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Summary  
Toll-like receptors (TLRs) play critical roles in human innate and adaptive immune 
responses and although they are well characterized, there remain gaps in our 
understanding of the early events upon TLR activation. In this thesis I assessed two 
different topics: first the regulation and function of MYD88 alternative splicing in B cell 
lymphomas and second, the role of the receptor TLR2 in the recognition of the very 
abundant natural agonist chitin. 
 
First topic: MyD88, a pivotal signaling protein for almost all TLRs, has been determined as 
an oncogenic driver in numerous cancers especially in Non-Hodgkin B cell lymphomas  
(B-NHL). Already in the 90’s, it has been found that the MYD88 gene undergoes 
alternative splicing. Alternative splicing is a mechanism used by eukaryotic cells to 
increase the complexity of gene expression by generating multiple proteins from a single 
gene. To date, five MyD88 isoforms were found in transcriptional analyses, but little is 
known about their natural occurrence and abundance in specific cell types. Furthermore, 
alternative splicing is often aberrant in cancers, resulting in novel protein isoforms which 
could originate or aid oncogenesis. In this study, I evaluated the hypothesis that MyD88 
alternatively spliced isoforms could be more highly expressed in B-NHL and might 
contribute to the well-studied oncogenic effect of MyD88. First, I tested whether the five 
known MyD88 isoforms could activate the pro-inflammatory and pro-survival 
transcription factor NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells). 
Using a reporter assay in HEK 293T cells, I found that three out of the five were able to 
induce NF-B activity. Furthermore, I confirmed expression of all isoforms by 
quantification of MyD88 transcripts from healthy and lymphoma B cells performing qPCR 
and RNAseq data analysis. Finally, deeper analysis of RNAseq data revealed the existence 
of two novel isoforms and demonstrated that MYD88 alternative splicing seems to be 
suppressed in B cell lymphomas. Thus, although results neglected the hypothesis that 
MyD88 alternative isoforms contribute to oncogenic signals in B-NHL, this study opens 
the possibility to attribute different roles to the isoforms especially in healthy conditions; 
for example, supporting the highly dynamic early events in MyD88-signaling.  
 
Second topic: Chitin is the second most abundant polysaccharide in nature and has been 
linked to fungal infection and allergic asthma. To date, several different receptors have 
been proposed to recognize chitin and evoke an inflammatory response. However, 
literature presents contradictory results and the physical binding of immune receptors to 
chitin has not been shown. Colleagues and I speculated that the discrepancies might be 
due to chitin’s highly polymeric nature and the use of crude extracts from crustaceans or 
fungi with variable purity as chitin preparations. Thus, here we proposed to use defined 
chitin (N-acetyl-glucosamine) oligomers comprising 4 to 15 subunits to overcome these 
limitations. We identified chitin made up of 6 subunits as the smallest immunologically 
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active chitin motif and a mixture of 10 to 15 chitin subunits showed the highest activity in 
innate immune cells. Using this mixture to stimulate bone marrow derived macrophages 
from different knockout mice enabled us to identify TLR2 as a specific chitin-receptor. 
Furthermore, we supported this finding by showing that mutations within the TLR2 
ligand-binding pocket impaired TLR2 responses to chitin. Additionally, we could block the 
chitin induced response with the known TLR2 antagonist, staphylococcal superantigen-
like protein 3 (SSL3). At last, we looked for the TLR2 co-receptor responsible to support 
chitin recognition. Based on data we suggest TLR1 and TLR6 as co-receptor candidates. 
Thus, this study found that chitin is recognized by TLR2 in mammals and proposes the 
chitin-TLR2 interaction as an attractive therapeutic target in chitin-related pathologies 
and fungal diseases.  
   
Overall, this doctoral thesis contributes new insights into MyD88 and its previous 
uncharacterized alternative splicing in B cells and describes the molecular details of TLR2 
recognition of chitin. 
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Zusammenfassung 
Toll-like-Rezeptoren (TLRs) spielen eine wichtige Rolle in der humanen angeborenen und 
adaptiven Immunität. Obwohl TLRs gut charakterisiert sind, bleiben Lücken in unserem 
Verständnis der frühen Ereignisse nach TLR-Aktivierung. In dieser Arbeit untersuchte ich 
zwei Aspekte: Die Regulation und Funktion von alternativen Spleißvarianten des TLR 
Adapterproteins MyD88 in B-Zell-Lymphomen sowie die Rolle des Rezeptors TLR2 bei der 
Erkennung des Agonisten Chitin, einem in der Natur sehr häufig vorkommenden 
Polysaccharid. 
 
Erstes Projekt: MyD88, ein wichtiges Adapterprotein, das Signale von fast allen aktivierten 
TLRs weiterleitet, ist häufig in verschiedenen B-Zellen Non-Hodgkin-Lymphomen (B-NHL) 
mutiert und trägt dadurch maßgebend zur Krebsentstehung bei. In den 90er Jahren 
wurde bereits herausgefunden, dass MyD88 alternative Spleißvarianten aufweist. 
Alternatives Spleißen ist ein Mechanismus, der von eukaryotischen Zellen verwendet 
wird. Dabei werden mehrere Proteine aus einem einzelnen Gen erzeugt, um die 
Komplexität der Genexpression zu erhöhen. Bislang wurden 5 MyD88-Isoformen in 
Transkriptom-Analysen gefunden, aber es ist wenig über das natürliche Vorkommen und 
die Häufigkeit von alternativen MyD88-Isoformen in spezifischen Zelltypen bekannt. 
Daher untersuchte ich hier alternatives Spleißen von MyD88 in humanen B-Zellen und  
B-NHL.  
Meine Hypothese war, dass die alternativen Isoformen in Lymphomen stärker exprimiert 
würden und dadurch zu der onkogenen Wirkung von MyD88 beitragen könnten. Zunächst 
testete ich, ob die 5 bekannten MyD88-Isoformen den Transkriptionsfaktor NF-B 
(nuclear factor kappa-light-chain-enhancer of activated B cells) aktivieren konnten. 
Mithilfe eines Reporter-Assays in HEK 293T-Zellen fand ich heraus, dass 3 von 5 Isoformen 
NF-B-Aktivität induzieren konnten. Danach habe ich die Expression der Isoformen durch 
Quantifizierung von MyD88-mRNA-Molekülen aus gesunden und lymphomen B-Zellen 
durch qPCR- und RNAseq-Datenanalyse nachgewiesen. Zusätzlich deckte eine tiefere 
Analyse der RNAseq-Daten die Existenz von zwei neuen Isoformen auf und zeigte, dass 
alternatives Spleißen von MyD88 in B-Zell-Lymphomen unterdrückt zu sein scheint. 
Obwohl alternative MyD88-Isoformen nicht zur MyD88-Onkogenese beitragen, 
ermöglicht diese Studie MyD88 Isoformen unterschiedliche Rollen zuzuordnen. 
Beispielsweise als wichtiger Unterstützer bei der Entstehung des MyD88 Komplexes oder 
bei neuen Protein Interaktionen. 
 
Zweites Projekt: Chitin ist das zweithäufigste in der Natur vorkommende Polysaccharid 
und wurde mit Pilzinfektionen und allergischem Asthma in Verbindung gebracht. Bis 
heute wurden mehrere verschiedene Rezeptoren vorgeschlagen, um Chitin zu erkennen 
und eine entzündliche Reaktion auszulösen. Dennoch zeigt die Literatur widersprüchliche 
Ergebnisse und die physikalische Bindung von Immunrezeptoren an Chitin wurde nicht 
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gezeigt. Meine Kollegen und ich haben vermutet, dass die Diskrepanzen auf Chitins 
hochpolymerer Natur und die Verwendung von Rohextrakten aus Krustentieren oder 
Pilzen mit variabler Reinheit als Chitinpräparate zurückzuführen sein könnten. Meine 
Kollegen und ich haben vermutet, dass diese Diskrepanzen auf die chemische 
Heterogenität von verwendeten Chitin-Präparaten zurückzuführen sind, welche häufig als 
Rohextrakte aus Krustentieren oder Pilzen mit variabler Reinheit gewonnen werden. Um 
diese Ungenauigkeiten auszuschließen, verwendeten wir definierte Chitin Oligomere aus 
4 bis 15 N-Acetylglucosamin Untereinheiten. Wir identifizierten, dass mindestens sechs 
dieser Untereinheiten für eine immunologische Reaktion nötig sind. Eine Mischung von 
Chitin Oligomeren bestehend aus 10 bis 15 N-Acetylglucosaminen zeigte dabei die 
höchste inflammatorische Reaktion in angeborenen Immunzellen. Anhand von Versuchen 
mit Makrophagen aus dem Knochenmark von verschiedenen Knockout Mausstämmen, 
konnten wir TLR2 als spezifischen Rezeptor für oligomeres Chitin identifizieren. Darüber 
hinaus konnten wir zeigen, dass Mutationen in der TLR2 Ligandenbindungstasche die 
Aktivierung von Chitin reduzierten. Außerdem konnten wir die durch Chitin 
hervorgerufene Immunaktivierung mit dem TLR2-Antagonisten Staphylococcus 
Superantigen-like Protein 3 (SSL3) blockieren. Weiterhin suchten wir nach einem Co-
Rezeptor für TLR2, der die Chitin Erkennung sowie Signalübertragung unterstützen 
könnte. Ausgehend von unseren Untersuchungen schlagen wir TLR1 und TLR6 als 
Unterstützer vor.  
Diese Studie zeigt, dass Chitin, sowohl im Menschen als auch bei Mäusen, durch TLR2 
erkannt wird. Daher schlagen wir die Chitin-TLR2-Interaktion als therapeutischen 
Angriffspunkt gegen Chitin-assoziierten Pathologien und Pilzkrankheiten vor. 
 
Insgesamt stellt diese Doktorarbeit neue Erkenntnisse zu MyD88 und seinen bisher nicht 
charakterisierten alternativen Isoformen in B-Zellen vor und beschreibt die molekularen 
Details der Erkennung von Chitin durch den Rezeptor TLR2. 
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Chapter 1: General Introduction 
1.1 Innate and Adaptive immune system  
 
The immune system is the second most complex system of eleven in the human body, 
which has been exhaustibly studied at distinct levels of structural organizations from 
organisms to molecules, but still not fully understood. The function of the immune system 
is to maintain homeostasis of the host by inducing defense mechanisms in the presence 
of microbes or danger signals resulting from e.g. tissue damage. In mammals, there are 
three levels of host defense: 1) physiologic barriers, 2) innate immunity and 3) adaptive 
immunity (Turvey and Broide 2010, Iwasaki and Medzhitov 2010), and here I focus on the 
last two. 
 
After an intruder was able to overtake the physiologic barriers as e.g. the skin, the innate 
immunity defense mechanisms play crucial roles in the earliest phases of infection and 
may succeed in eradicating the pathogen. Innate immune protection is a task performed 
by cellular processes done by hematopoietic and nonhematopoietic cells, and humoral 
components. On one hand cellular processes start with the recognition of the pathogen 
by pattern recognition receptors, the induction of pro-inflammatory signaling pathways 
and end with the awakening of elimination mechanisms, e.g. phagocytosis (Turvey and 
Broide 2010). In brief, phagocytosis is the cellular uptake of particles/pathogens below  
5 µm initiated by receptor-ligand interactions. Once the pathogen is internalized, the 
phagosome fuses to lysosomes, vesicles which contain hydrolytic enzymes and maintain 
an acidic environment (pH 4.5). Thus, the fusion of these two types of organelles, 
phagosome and lysosome, results in progressive acidification and digestion or the cargo 
(Gordon 2016, Pauwels et al. 2017). On the other hand, humoral components such as 
complement proteins, Lipopolysaccharide (LPS) binding proteins, antimicrobial peptides, 
among others (Turvey and Broide 2010), are able to opsonize and lyse cells, and have 
potent inflammatory activity. As example of together work of cellular processes and 
humoral components is the function of complement proteins to opsonize pathogens to 
facilitate phagocytosis (Frank 2010).  
 
Pathogens, however, developed strategies that allow them to overcome these 
mechanisms. In these circumstances, the innate immune system is able to induce an 
adaptive immune response which takes several days to build up the tools needed to 
eliminate the pathogen (Iwasaki and Medzhitov 2015, Turvey and Broide 2010). It 
requires clonal differentiation and expansion of naïve lymphocytes into antibody-
secreting B cells and effector T cells. Then, the adaptive immunity performs an efficient 
antigen-specific protection through highly specific antigen receptors, namely B-cell and T-
cell receptors and immunoglobulins. These receptors are assembled through somatic 
recombination and therefore provide immense diversity to recognize antigens, while they 
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have also passed selection processes to avoid self-recognition. The long lasting and 
effective protection by the adaptive immunity is achieved also by its capacity for memory, 
which allows a greater and more rapid response against recurrently invading 
microorganisms (Gregersen and Behrens 2006, Janeway 2001). In contrast, innate 
immunity is considered as pattern-specific protection responding to evolutionary 
conserved structures of microbes through germline-encoded receptors known as pattern 
recognition receptors (PRRs). The engagement of PRRs with their specific molecular 
pattern (referred to also as ligand) activates intracellular signaling cascades that lead to 
the production of pro-inflammatory or anti-inflammatory cytokines and chemokines, 
which regulate processes such as activation, migration and differentiation of immune 
cells to develop an effective and pathogen-specific adaptive immune response (Murray 
and Wynn 2011, Rivera et al. 2016). 
 
The high complexity of the immune system is also attributed to the cross-talk between 
innate and adaptive immunity. Communication between the two systems requires cell-
cell interaction or external soluble signals such as cytokines and immunoglobulins (Zhang 
and An 2007).  Antigen presentation is one example in which the innate system activates 
the adaptive system by cell-cell interaction. Upon activation via PRRs, a professional 
antigen presenting cell, e.g. a dendritic cell, presents an antigen from an engulfed 
microbe to a T cell together with co-stimulatory signals. Then, the T cell recognizing the 
presented antigen will expand efficiently and develop an effector function (den Haan, 
Arens, and van Zelm 2014). On the other hand, activated T cells can produce cytokines to 
recruit and stimulate phagocytic innate immune cells such as macrophages, who engulf 
pathogens or support healing processes (Kawakami et al. 1995, Gordon 2016, Smigiel and 
Parks 2018).  
 
A system as complex as the immune system needs sophisticated regulatory mechanisms. 
Failure in its regulation can lead to a large number of diseases, such as inflammatory 
diseases due to an exaggerated response (e.g. allergy, asthma, Crohn’s disease), 
autoimmune diseases due to unwarranted reactions against self-molecules (e.g. systemic 
lupus erythematosus, type 1 diabetes, rheumatoid arthritis), or cancer (Coussens and 
Werb 2001, Gregersen and Behrens 2006). However, a weak immune system, e.g. due to 
genetic diseases or other factors (e.g.  HIV, drug use), often leads to recurring and life-
threatening infections (Maarschalk-Ellerbroek et al. 2012).   
 
1.2 Pattern recognition receptors and pathogen sensing  
 
Pattern recognition receptors are germline-encoded receptors broadly expressed on the 
cell surface, internal membranes or within the cytoplasm of multiple cell types including 
blood cells, epithelial cells, nerve cells and others. Innate immune cells express the 
highest levels of PRRs. These receptors are important players in the innate immunity 
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since they are the first ones to recognize and classify the type of intruder or malignancy 
(e.g. cancer) that appears within a mammalian organism (Tan et al. 2014, Janeway 2001). 
Receptors recognize microbe-associated molecular pattern (MAMP) coming from e.g. 
bacteria, virus and fungi or a danger-associated molecular pattern (DAMP) appearing 
after tissue damage. Depending on which receptor is engaged and whether a MAMP or a 
DAMP has been recognized, the receptor signaling initiates an exclusive type of immune 
response against the specific microbe or danger signal (Newman et al. 2013, Rivera et al. 
2016).   
PRRs are classified in five families: 1) Toll like receptors (TLRs), 2) C-type lectin receptors 
(CLRs), 3) Retinoic acid-inducible gene-I-like receptors (RLRs), 4) NOD-like receptors 
(NLRs) together with absent in melanoma 2 (AIM2)-like receptors (ALRs) and 5) cytosolic 
DNA receptors. All families are specialist, but not exclusive, in recognizing certain 
microbes. For example RLRs mainly recognize molecular patterns of RNA viruses, cytosolic 
DNA receptors sense DNA and RNA viruses, CLRs detect MAMPs of fungi and NLRs 
identify mostly bacterial dipeptides (reviewed in (Brubaker et al. 2015, Takeuchi and Akira 
2010, Gay et al. 2014, Ma and Damania 2016)). On the other hand, TLRs cover ligands 
from all type of microbes.  
 
1.3 Toll-like receptors  
 
1.3.1 Toll-like receptors and their corresponding ligands  
 
The TLR family of PRRs senses MAMPs derived from bacteria, fungi, viruses and protozoa. 
Additionally, they can also recognize endogenous DAMPs from distressed, injured or 
necrotic cells (for a detailed list of TLR-ligands, see Table 1) (Braza et al. 2016, Gay et al. 
2014). Besides being highly expressed in innate immune cells, such as macrophages or 
dendritic cells, TLRs are also expressed at lower levels in epithelial and endothelial cells, 
adipocytes, cardiac myocytes and some other cell types (Akira, Takeda, and Kaisho 2001). 
To date, 10 Toll-like receptors in humans (TLR1-10) have been identified, 13 in mouse 
(TLR1-13) and other fish-specific like TLR18 and TLR22 in Cyprinus carpio L. carp fish (Shan 
et al. 2017, Li et al. 2017, O'Neill, Golenbock, and Bowie 2013).   
TLRs are type I transmembrane receptors and their characteristic domain architecture 
comprises a leucine-rich repeat ectodomain that mediates the recognition of the 
molecular patterns, a transmembrane domain and an intracellular Toll-interleukin 1 
receptor (TIR) domain, which initiates downstream signal transduction. Based on their 
subcellular localization, TLRs can be divided into two groups: 1) TLR1, TLR2 and TLR6 are 
expressed in the plasma membrane and recognize lipopeptides; TLR4 recognizes LPS; 
TLR5 binds flagellin; and TLR11 and TLR12 bind MAMPs from uropathogenic bacteria. The 
TLR10 ligand remains to be elucidated. 2) The nucleic acid receptors TLR3, TLR7 and TLR8, 
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TLR9 and TLR13are expressed in endosomes and recognize dsRNA, ssRNA, CpG motifs 
derived from bacterial and viral DNA, and ribosomal RNA respectively (Akira, Takeda, and 
Kaisho 2001, O'Neill, Golenbock, and Bowie 2013).  
In the inactive state most TLRs are monomeric and require dimerization to induce 
downstream signaling, with the exceptions of TLR7, 8 and 9 which exist as preformed 
dimers and their ectodomains need to be cleaved by endoproteases within acidified 
endolysosomes to start the signal transduction (Ewald et al. 2008, Gay et al. 2014). 
Another special TLR is TLR2, which increases the variety of ligands by forming 
heterodimers with TLR1, TLR6 and possibly TLR10 (Gay et al. 2014, Oosting et al. 2014). 
An additional example is the heterodimer of mouse TLR11 and TLR12 to recognize the 
protein profilin from Toxoplasma gondii (Koblansky et al. 2013). Amongst the TLRs, TLR4 
is unique because in addition to homodimerization its activation also requires the co-
receptor myeloid differentiation factor 2 (MD2) (Lu, Yeh, and Ohashi 2008).  
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Table 1. List of known TLR-ligands 
 
 
 
 
 
 
 
 
 
TLRs Type of ligand Ligands
Bacterial
Bacterial lipopeptides, peptidoglycan, lipoteichoic acid (LTA), Porin B 
Lipopolyssacharide (LPS), lipopeptides from Mycoplasma and Spirochetes. 
Lipoarabinomannan, mannosylated phosphatidylinositol from Mycobacteria. 
Fungal Chitin and Zymosan
Parasitic Glycophosphatidylinositol-anchored proteins
Endogenous Cardiac myosin
Bacterial Triacylated lipopeptides, peptidoglycan, LTA.
Synthetic Pam3CSK4
Bacterial Diacylated lipopeptides, peptidoglycan, LTA. 
Endogenous Necrotic cell content from any cell type.
Synthetic Pam2CSK4, FSL-1, MALP-2 [Invivogen].
Viral double-stranded RNA
Endogenous RNA sequences, HMGB1*
Synthetic Polyinosinic:polycytidylic acid, known as Poly(I:C)
Bacterial
LPS, lipid A. Live Mycobacteria tuberculosis  and Treponema brennaborense 
glycolipids.
Viral Respiratory syncytial virus protein F
Endogenous Heat shock protein 60*,70*,90*, fibrinogen 6, Defensin 2.
Plant Taxol
TLR5 Bacterial Flagellin
Viral single- stranded viral RNA
Endogenous Host nucleic acids like uridine-rich RNAs
Synthetic Synthetic chemical imiquimod, Azoquinolines, R-848.
Viral Single-stranded viral RNA
Endogenous Host nucleic acids, cardiac myosin. 
Synthetic Azoquinolines, R-848.
Bacterial CpG rich hypomethylated DNA motifs 
Viral Herpesvirus DNA, MCMV in IPCs
Endogenous CpG in autoantibody complexes, HMGB1*
Synthetic Azoquinolines
Bacterial Viable Listeria monocytogenes
Synthetic anti-TLR10 antibody (cross-linker)
TLR11 (mouse) Bacterial Component of uropathogenic bacteria, profilin-like molecules
TLR13 (mouse) Bacterial Ribosomal RNA
TLR11 with TLR12 
(mouse)
Parasitic Toxoplasma gondii  profilin protein
TLR10 (human)
TLR8
TLR9 
TLR7 
TLR2 
TLR2 with TLR1 
TLR2 with TLR6
TLR3 
TLR4 with MD2 
Table modified and completed from O'Neill, 2013. *controversial findings due to possible contaminated 
samples. List of references were summarized in Table S1.  
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1.3.2 Molecular steps in Toll-like receptor signaling 
 
Ligand-induced dimerization and conformational changes in TLRs initiate downstream 
signaling cascades. TLR activation induces several signaling cascades. TLRs trigger 
activation of canonical nuclear factor kappa-light-chain enhancer of activated B cells  
(NF-B), mitogen-activated protein kinase (MAPK) and Interferon regulatory factor 5 (IRF-
5) pathways leading to expression of pro-inflammatory cytokines and chemokines, and 
they activate the Phosphoinositide 3-kinase (PI3K) pathway promoting cell survival. Some 
TLRs can also trigger transcription of antiviral type I IFN (interferon) via IRF3 and IRF7 
(Gay et al. 2014, Stack et al. 2014) (See Fig.1).  
Upon ligand engagement, the intracellular TIR domains of the TLRs come together, 
forming a platform that recruits one or two out of six TIR domain-containing adaptor 
proteins, such as MyD88 (myeloid differentiation primary response protein 88), MAL 
(MyD88 adaptor-like protein), TRIF (TIR domain-containing adaptor protein inducing 
IFN), TRAM (TRIF-related adaptor molecule), SARM (Sterile alpha and armadillo motif-
containing protein) and BCAP (B-cell adaptor for Phosphoinositide 3-kinase) (Bernard and 
O'Neill 2013, O'Neill et al. 2003). This section only describes the MyD88/MAL and 
TRIF/TRAM-signaling pathways.  
Activation of the MyD88-pathway requires the formation of the big signaling complex 
called Myddosome, whose assembly is detailed described in Section 1.4.1. This complex 
induces the activation of several transcription factors through distinct signaling-pathways. 
NF-B activation is induced by the recruitment and activation of the E3 ubiquitin ligase, 
TNFR-associated factor 6 (TRAF6) to the Myddosome complex. Once activated, TRAF6 is 
released into the cytosol where it triggers the degradation of the IB(inhibitor of  
NF-B leading to activation and nuclear translocation of NF-B. In parallel, TRAF6 also 
activates IRF5 and prompt the MAP kinase pathway to activate AP-1 and CREB (Gay et al. 
2014) (Fig.1). Through the activation of the transcription factors NF-B, AP-1, CREB and 
IRF-5 an array of genes are expressed, which mediate the production of pro-inflammatory 
cytokines such as TNF-α, IL-12, IL-6, IL-8 and IL-1β, the anti-inflammatory cytokine IL-10 
and chemokines like CCL2, CCL3, CCL5 and CXCL10 (Gurtler et al. 2014).  
The TRIF-dependent pathway leads to phosphorylation and activation of transcription 
factor IRF3, when the N-terminal domain of TRIF interacts with TRAF3 (TNF receptor-
associated factor 3), TBK1 (TRAF family member-associated NF-kappa-B activator binding 
protein 1) and the members of the inhibitor of NF-B kinase family: IKKi and IKKTRIF-
dependent activation of IRF7 requires IRAK1 instead of TBK1. Moreover, this pathway can 
initiate apoptosis via receptor interacting protein 1 (RIP1) and caspase-8, and NF-B 
activation via TRAF6. TRIF’s TIR domain mediates interaction with the TLRs and TRAM. 
These TRIF-pathways lead to the expression of the antiviral type I interferon, such as  
IFN-. In unstimulated cells, the N-terminal and the TIR domains allow self-association, 
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thereby blocking interaction with the downstream signaling molecules and making TRIF a 
negative regulator of its own pathway (Gay et al. 2014, Ullah et al. 2016).  It is important 
to mention that there is an extensive crosstalk between the IRF and NF-B pathways, 
making it very complex to determine the signaling pathway engaged by a specific ligand 
(Iwanaszko and Kimmel 2015). 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MyD88 and TRIF signaling steps until the activation of transcription factors.   
Adapted from Gay, et al. IRAK, interleukin-1 receptor-associated kinase; TRAF, tumor necrosis factor 
receptor-associated factor; TAK1, TGFβ-activated kinase 1; TAB, TAK1-binding protein; IKK, inhibitor of  
NF-B kinase; IBα, inhibitor of NF-Bα; MKK, mitogen activated protein kinase kinase; JNK, JUN  
N-terminal kinase; AP-1, activator protein 1; CREB, cAMP-responsive element-binding protein; TBK1, 
TANK-binding kinase 1; IRF, Interferon regulatory factor.  
Myddosome 
Endosomal or  
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1.3.3 Toll-like receptor signaling in Disease 
 
TLR signaling is essential for a functional immune system. Nevertheless, uncontrolled 
activation of the pathway or sustained exposure to agonists results in excessive 
inflammation and tissue damage giving rise to 1) inflammatory diseases such as bowel 
inflammation and asthma, and 2) autoimmune diseases as multiple sclerosis, systemic 
lupus erythematosus and rheumatoid arthritis (Drexler and Foxwell 2010).  
 
Absence or exaggeration of TLR signaling is also associated to hematopoietic and 
lymphoid malignancies, and promotion of oncogenesis in general. The common effect of 
TLRs in these malignancies is a chronic TLR signaling caused by gain-of-function 
mutations, increased expression of the signaling molecules or sustained exposure to 
agonists (Monlish, Bhatt, and Schuettpelz 2016). The amplified signaling leads to survival 
and proliferation of the affected cell via the activation of specific transcription factors and 
resulting cytokine production as described before.   
Aberrant TLR signaling frequently happens outside of their well-known role in immune 
cells, influencing e.g. differentiation and proliferation of hematopoietic stem cells. 
Continuous signaling diminishes hematopoietic stem cell capacity for self-renewal and 
favors myeloid differentiation, giving rise to diseases like Myelodysplastic syndromes and 
leukemia. Relevant aberrations include: TLR2-F217S variant or increased TRAF6 activity 
due to deletion of 5q in Myelodysplastic syndromes (Starczynowski et al. 2010, Wei et al. 
2013). Furthermore, examples for oncogenic promotion are well described in lymphomas, 
leukemias and colon, breast and lung cancer mainly by overexpression of TLR signaling 
members linked to worse prognosis (e.g. MyD88 and TLR2) (Monlish, Bhatt, and 
Schuettpelz 2016, Ngo et al. 2011, Wang et al. 2013, Muzio et al. 2009).  
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Chapter 2: Assessing MyD88 alternative splicing in B cells and 
Lymphomas 
 
2.1 Introduction 
 
2.1.1 Myeloid differentiation primary response 88, MyD88 
 
Myeloid differentiation primary response 88 (MyD88) is a well characterized pivotal 
adaptor protein participating in signaling pathways in innate and adaptive immunity. The 
human and murine coding sequences comprise 296 amino acids, forming a 33 kilo-Dalton 
protein. The sequences of the three main domains, which determine its functionality and 
interactions, are well conserved. The TIR domain at the C-terminus binds to the TIR-
domains of all Toll-like receptors (except for TLR3) and the Interleukin-receptor members 
IL-1-R and IL-18-R upon receptor engagement. The N-terminal death domain (DD) 
interacts with downstream signaling proteins, thereby mediating the formation of a 
signaling complex. At last, the intermediate domain is suggested to be important for 
conformational changes, allowing MyD88 to transmit signal (Avbelj, Horvat, and Jerala 
2011, Deguine and Barton 2014, von Bernuth et al. 2012). MyD88 has been intensely 
studied as the main player of the MyD88-dependent pathway in innate immune cells. 
However, the MyD88 somatic mutation leucine to proline in position 265 has move the 
attention of this pathway to adaptive immune cells, where many things remain to be 
discovered to understand the crucial differences limited to specific cell types (Ngo et al. 
2011, Wang et al. 2014).  
 
2.1.2 Molecular steps in MyD88 signaling complex assembly  
 
Most of the knowledge about TLR signaling has been gained from innate immune cells 
like human and murine plasmacytoid or myeloid dendritic cells, primary monocyte 
derived macrophages and monocyte or macrophage cell lines. Thus, the downstream 
signaling steps of MyD88 presented in this section are the result of studies in innate 
immune cells.  
During MyD88-dependent signaling, MyD88 functions as a scaffold protein for the 
interaction and activation of several serine-threonine kinases from the IL-1 receptor-
associated kinase (IRAK) family. IRAK1, IRAK2, and IRAK4 are positive activators and 
IRAK3, also known as IRAKM, is a negative regulator. IRAKM is the only IRAK that doesn’t 
have a kinase activity and its expression is induced, whereas others mediate their 
activation through self-phosphorylation events and are ubiquitously expressed (Gosu et 
al. 2012). The interaction between MyD88 and the IRAKs is mediated by their respective 
N-terminal DDs, resulting in the assembly of a multi-protein signaling complex named the 
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“Myddosome”. A crystal structure of the DDs within the Myddosome revealed that the 
complex comprises six MyD88, four IRAK4 and four IRAK1 or IRAK2 molecules assembled 
into a helical tower-shaped structure. Furthermore, assembly of the Myddosome is 
thought to occur in a sequential manner: MyD88 binds IRAK4 and MyD88/IRAK4 then 
recruit IRAK1 or IRAK2. The assembled Myddosome complex allows the kinase domains of 
IRAK4 to phosphorylate themselves and IRAK1 or IRAK2, leading to IRAK1/2 
autophosphorylation (Fig.1). This step-sequence suggests IRAK4 kinase activity as key 
point for downstream signaling (Lin, Lo, and Wu 2010). Nevertheless, Vollmer et al. 
proposed that IRAK1 catalytic activity turns on just by an allosteric mechanism binding to 
IRAK4, meaning that IRAK4 kinase activity is not necessary for IRAK1 autophosphorylation 
(Vollmer et al. 2017). Next, IRAK1/2 autophosphorylation prompt recruitment of the E3 
ligase TRAF6 leading to MyD88-dependent activation of NF-B, MAPKs and IRFs as 
described above in Section 1.3.2 (Conze et al. 2008, Lin, Lo, and Wu 2010, Schauvliege, 
Janssens, and Beyaert 2007).  
  
2.1.3 MyD88 signaling variations in B cells 
 
TLR expression in adaptive immune cells like B cells and T cells is low in comparison to 
innate immune cells. Nevertheless, TLRs play critical roles in the development of an 
efficient adaptive response. This section will focus on B cells. Expression levels of TLRs can 
vary depending on the B cell type, meaning that naïve B cells have very low levels of TLRs, 
and marginal zone B cells have the highest expression among B cell populations.  
 
TLR-MyD88 activation in MyD88-deficient B cells has shown its involvement in promoting 
class-switching and antibody production including germinal center formation, and plays a 
role in progression of autoimmune diseases (Hess et al. 2017, Hua and Hou 2013). Recent 
B cell non-Hodgkin lymphoma (B-NHL) RNA sequencing studies found a common somatic 
mutation in MyD88’s TIR-domain (p.L265P) that contributes to lymphomagenesis (Ngo et 
al. 2011). This finding boosted the interest to investigate similarities and differences of 
the MyD88 pathway in adaptive immune cells in comparison to innate immune cells.  
In general, the signaling pathways leading to the activation of NF-B, MAPKs and PI3K are 
suggested to be the same. In fact some findings were first discovered in B cells and 
proved later in macrophages, e.g. BCAP regulation of PI3K activation (Ni et al. 2012, 
Okada et al. 2000). Thus, both types of cells have been used to solve the complete TLR-
inducible signaling pathways. 
 
However, there are several TLR events exclusive for B cells. One distinction is the cross-
talk between TLR- and B cell receptor (BCR)-signaling, where TLR ligands enhance BCR 
signaling in the presence of low BCR antigen (Freeman et al. 2015, Wilson et al. 2015). 
Furthermore, both receptor pathways up-regulate the expression of transmembrane 
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activator and calcium-modulating cyclophilin ligand interactor (TACI) increasing the 
sensitivity of B cells to BAFF (B cell-activating factor) and APRIL (a proliferation-inducing 
ligand).  Briefly, TACI-signaling inhibits B cell expansion and promotes the differentiation 
and survival of plasma cells, thus it is an important immune response regulatory pathway. 
Recent data demonstrated the direct contribution of MyD88 in activating NF-B signals 
dependent on TACI. These signals can result in the expression of activation-induced 
cytidine deaminase (AID; an enzyme that is required for somatic hypermutation) and 
extrafollicular class-switch recombination in germinal centers, which are important 
events for antibody responses in a T cell-independent manner. Thus, MyD88 signaling in  
B cells is crucial for T-independent B cell responses (Rawlings et al. 2012).  
 
Moreover, further events were elucidated based on MyD88-L265P mutation studies. The 
direct binding of MyD88 to BTK (Bruton’s tyrosine kinase) increases BTK phosphorylation 
and kinase activity in MyD88-L265P diseases (Yang et al. 2013). Last, the breakthrough 
discovery was made that L265P mutated MyD88 can activate downstream signaling 
cascades without TLR engagement by spontaneous assembly of the Myddosome (Avbelj 
et al. 2014). 
 
 
2.1.4 MyD88 signaling in Disease  
 
The impact of MyD88-IRAK4-dependent signaling on protective immunity has been 
mostly elucidated using MyD88- and IRAK4-deficient mice. These mice have shown to be 
susceptible to a broad variety of pathogens including bacteria, viruses, fungi and 
parasites; not only did the knockout mice show enhanced pathogen growth in vivo in 
comparison to wild type mice, but their mortality was also increased at any age (Suzuki et 
al. 2002, Pennini et al. 2013). Conversely, in humans these deficiencies cause recurrent 
pyogenic infections, such as meningitis, osteomyelitis and sepsis by limited bacteria 
strains, e.g. Streptococcus pneumoniae, Staphylococcus aureus and Pseudmomonas 
aeruginosa (Picard et al. 2003, Picard et al. 2010). Although patients have been detected 
to have other pathogens like mycobacteria or Toxoplasma, these pathogens do not cause 
invasive infections as observed in mice. Patients carry heterozygous or even homozygous 
mutations in MyD88 or IRAK4 genes causing a loss-of-function phenotype. 40% of IRAK4-
deficient and 37,5% of MyD88-deficient patients of all cases published to date died during 
infancy, strongly suggesting that the MyD88-dependent pathway is relevant in early life, 
but dispensable in adulthood. With simple prophylaxis such as the use of antibiotics, 
vaccination and IgG substitution, several individuals survived into adolescence (Picard et 
al. 2010, von Bernuth et al. 2012).  
 
Although the MyD88 or IRAK4 deficiency is not limited to innate immune cells, the 
pathogenicity is attributed to the lack of induction of an inflammatory response coming 
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from these cells (Deguine and Barton 2014, von Bernuth et al. 2012). Interestingly, no 
gain-of-function mutations have been discovered in human innate immune cells. 
Continuous stimulation of TLRs and the constitutive activation of transcription factors 
such as NF-B and STAT3 in innate immune cells is known to exert pro-oncogenic activity 
by promoting cell proliferation and cell death resistance. In addition, the resulting 
constant cytokine secretion attracts many type of cells, thereby establishing a perfect 
microenvironment for tumor formation and growth. Thus, tumorigenic pathogens, mainly 
viruses, use the MyD88-dependent pathway to carry out their oncogenic effects by 
exhorting chronic inflammation (Swann et al. 2008, Wang et al. 2014).  
 
Interestingly, somatic mutations leading to a hyperactive phenotype are more common in 
adaptive immune cells. Polymorphisms in TLRs are known to increase the risk of non-
Hodgkin lymphoma (Purdue et al. 2009) and the L265P mutation in MyD88 contributes to 
the selection of B cell-malignant clones by inhibiting apoptosis and increasing 
proliferation through the specific activation of NF-B (Isaza-Correa et al. 2014). Therefore, 
therapeutic strategies concentrate on shutting down the MyD88-dependent pathway at 
the MyD88 level, since NF-B inhibitors have strong side effects.  
 
In this study, I am particularly interested in lymphomas described to have the somatic 
mutation c.794T>C in the MYD88 gene, which changes leucin to proline at amino acid 
residue 265 (p.L265P) summarized in Table 1. Of special interest is Diffuse Large B cell 
lymphoma (DLBCL), the most common fast-growing B-NHL, which has two main subtypes: 
1) Active B cell (ABC) type and 2) Germinal Center B cell (GCB) type. The ABC-DLBCL 
characteristics are a chronic BCR signaling due to gain-of-function mutations in the 
pathway and several recurrent aberrations like BCL2 and MYC translocations; additionally, 
~30% of ABC-DLBCL cases have the MyD88 L265P mutation (Ngo et al. 2011). Therefore, 
DLBCL cell lines were used as one model system in this study.  
 
Available therapies against DLBCL are limited, and prognosis is worse for the latter 
subtype due to the constant acquirement of mutations and consequent resistance to 
treatments. Some FDA-approved examples are Ibrutinib against BTK kinase activity and 
Fostamatinib against Syk (spleen tyrosine kinase), targeting the BCR-signaling pathway 
(Sandoval-Sus, Chavez, and Dalia 2016). Still in basic research are potential MYD88 
(Shiratori, Itoh, and Tohda 2017) and IRAK4 (Scott et al. 2017) inhibitors.  
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Table 2. List of Non-Hodgkin lymphomas with frequent MyD88 L265P mutation.  
B cell malignancy 
Frequency of 
L265P 
Reference 
Waldenström’s Macroglobulinemia 90% (54% MGUS) 
(Varettoni et al. 2013, Xu et al. 
2013) 
Primary central nervous B cell lymphoma 60-71% 
(Montesinos-Rongen et al. 2011, 
Lee et al. 2017) 
Primary cutaneous large B cell lymphoma, leg 
type 
61% (Pham-Ledard et al. 2014) 
Mucosa-associated lymphoid tissue lymphoma 7-9% 
(Ngo et al. 2011, Traverse-Glehen 
et al. 2013) 
Diffuse large B cell lymphoma 
6.5-8%                    
(29% ABC subtype) 
(Ngo et al. 2011, Choi et al. 2013)           
(Pasqualucci et al. 2011) 
Chronic lymphocytic leukemia 3-4% 
(Puente et al. 2011, Landau et al. 
2013) 
Ocular adnexal extranodal marginal zone 
lymphoma 
7% (Zhu et al. 2013) 
Splenic marginal zone lymphoma 4-5% 
(Pasqualucci et al. 2011) (Gachard 
et al. 2013) 
 
  
 
2.1.5 Alternative splicing of MYD88  
 
Constitutive (or canonical) splicing is a simple process applied to precursor messenger 
RNA (pre-mRNA) transcripts, in which introns are removed and exons are ligated in the 
order they appear in a gene to generate a single functional protein (Wang et al. 2015). 
RNA splicing in eukaryotes takes place in a big ribonucleoprotein complex called the 
spliceosome. Five small nuclear ribonucleoprotein complexes (U1, U2, U4/U6, and U5) 
dynamically recognize and assemble on introns to cleave and ligate RNA molecules for 
intron removal, generating the protein-coding mRNAs (Wahl, Will, and Luhrmann 2009). 
The spliceosome catalyzes splicing with high precision, but also displays high flexibility to 
regulatory signals for rapid responses. One of these regulatory signals is alternative 
splicing. Alternative splicing involves mechanical processes by which “alternative” splice 
sites in pre-mRNAs are selected, creating new junctions to produce multiple mature 
mRNAs. This allows the production of multiple proteins with potentially distinct 
structures and functions from a single gene (Fu and Ares 2014, Bonomi et al. 2013). 
Recent findings have determined that the average human gene can generate at least 3 
alternatively spliced isoforms. Thus, alternative splicing is a process used across kingdoms 
to expand the diversity and function of the proteome (Lee and Rio 2015). 
 
There are numerous mechanisms for alternative splicing, for example: RNA-RNA 
interaction from long-distance RNA, which facilitates the exchange of a common exon to 
an alternative exon; or most common, RNA-protein interactions, where splicing factors 
bind to regulatory sites such as silencers or enhancers, thereby changing splicing 
patterns. Systematic analysis of RNA data has revealed several types of alternative 
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splicing: 1) exon skipping, 2) alternative 5’ and 3’ splice sites within exon or intron 
sequences, which often lead to subtle changes in the coding sequence and 3) intron 
retention, which frequently generates premature termination codons (Wang et al. 2015).   
 
MyD88 alternative splicing generates four isoforms (1, 3, 4 and 5) found in genomic and 
RNA sequence analysis deposited on NCBI’s Reference Sequence database, besides the 
canonical MyD88 isoform 2. Isoforms 3, 4 and 5 are generated by exon skipping and 
isoform 1 by an alternative splice site within the 3rd intron. For a detailed description of 
MyD88 alternative isoforms see Figure 2.  
 
Some alternative splicing events seem to be constitutive resulting in the co-existence of 
isoforms at constant ratios in the same cell, while others are regulated by signal 
responses. In the case of MyD88, its alternative splicing has been proposed to be 
regulated by TLR responses in macrophages, although it has been only shown for the 
expression of MyD88 isoform 3 (Adib-Conquy et al. 2006, Burns et al. 2003, Janssens et al. 
2003). Furthermore, the splicing factors SF3A and SF3B were also found to control 
production of MyD88 isoform 3 in murine myeloid cells (De Arras and Alper 2013). Thus, 
isoform 3 remains the only isoform to be, although little studied. Therefore, an aim of this 
project is to elucidate the regulation of the other known but uncharacterized splice 
variants (Isoforms 1,4 and 5), whose so far associated knowledge is summarized in  
Table 3.  
 
Alternative splicing in oncogenesis is frequently dysregulated and has been considered as 
another hallmark of cancer (Ladomery 2013). Alternative splicing can be frequently 
manipulated by polymorphisms within splice sites resulting in the generation of new 
isoforms which can originate or support oncogenesis (Kaida, Schneider-Poetsch, and 
Yoshida 2012, Wang et al. 2015). However, the here studied MyD88 alternative isoforms 
are not generated by polymorphisms. Nevertheless, it will be important to characterize 
splice isoforms of key proteins in a healthy vs. oncogenic scenario.  
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Table 3. Current knowledge about MyD88 isoforms 
  Human Mouse Reference 
Known sequences 1-2-3-4-5 2-3 Genbank, Uniprot 
Isoform 2       
Referred as "Canonical" sequence "Canonical" sequence Genbank, Uniprot 
Associated with 
oncogenesis 
MyD88 L265P mutation 
(hyperactive phenotype) 
DLBCL, CLL 
MyD88 L252P mutation 
DLBCL-like phenotype 
(Ngo et al. 2011, 
Avbelj et al. 2014, 
Knittel, Liedgens, 
and Reinhardt 
2015) 
Isoform 3       
Referred as MyD88 short MyD88 short   
Expression induction 
Monocytes stimulated 
with LPS (sepsis). 
Bronchial epithelial cells 
treated with resveratrol  
Monocytes and 
macrophages stimulated 
with LPS and IL-1ß. 
Resveratrol treatment in 
lung epithelial cells. 
(Adib-Conquy et al. 
2006, Janssens et 
al. 2003, Andrews 
et al. 2016)  
Function 
Tolerance to TLR2 and 
TLR4 re-stimulation.  
Inhibit NF-B but not JNK 
pathway (mouse 
constructs in MEF cells). 
Decreases inflammation in 
the lung of mice via 
inhibition of ERK1/2 
(Adib-Conquy et al. 
2006, Burns et al. 
2003) 
Molecular 
mechanisms 
Suggested to be the 
same as in mouse 
Sequesters Isoform 2 
impairing binding to IRAK4 
(Burns et al. 2003) 
Isoform 1, 4 & 5       
Expression induction Not known Not known   
Function Not known Not known   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DLBCL: Diffuse Large B Cell Lymphoma; CLL: Chronic Lymphocytic Leukemia; MEF cells: murine embryonic 
fibroblast 
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2.2 Hypothesis and aims 
 
MyD88 has been intensely studied as the main player of the MyD88-dependent pathway 
in innate immune cells. However, the MyD88 somatic mutation L265P has moved the 
attention to adaptive immune cells due to its oncogenic power. Many things about this 
molecule and pathway remain to be discovered to understand the crucial differences 
between specific cell types. The background of this project are the following facts: First, 
the L265P mutation confers a hyperactive phenotype leading to the constitutive 
activation of NF-B which drives oncogenesis. Second, it has been shown that MyD88 
isoform 3 expression can be induced by continuous stimulation with LPS, theoretically via 
NF-B.  
 
Therefore, I hypothesized that the expression of alternative isoforms is increased in B cell 
lymphomas versus healthy B cells. B cell lymphomas are known to have a constitutive 
activation of the NF-B pathway to e.g. mediate survival. These alternative isoforms are 
expected to regulate MyD88 signaling possibly in a negative way as demonstrated for 
isoform 3 or as positive feedback loop contributing to oncogenesis. The aim of this 
chapter was therefore to investigate whether the expression pattern of MyD88 isoforms 
would change in B cell lymphomas in comparison to healthy B cells and whether any of 
alternative splicing products would drive oncogenesis.  
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2.3 Results 
 
MyD88 alternative splicing generates four extra isoforms besides the reference protein; 
only one of them has been little studied, whereas the others have so far remained 
annotations. Considering isoforms as different forms from the same protein, theoretically 
alternative isoforms can have the same or distinct function as the reference, depending 
on the changes at the mature mRNA and subsequent protein level. Thus, I first generated 
constructs of each MyD88 isoform and evaluated their ability to induce NF-B activity to 
solve their function. Then, I confirmed their physiological transcription and protein 
expression by RNAseq data analysis and immunoblotting, using samples from several  
B-NHLs.  I evaluated also different conditions to test how alternative splicing could be 
regulated, quantifying expression levels of the isoforms upon different treatments in B 
cells by qPCR. At last a deep analysis of the RNAseq data gave us quantitative 
transcription levels of the isoforms in different B-NHLs and this data gave hints of new 
isoforms that were not annotated before. 
 
 
2.3.1 Generation of MyD88 isoforms plasmids 
 
Genomic and RNA sequence analysis showed the existence of MyD88 alternative isoforms 
1, 3, 4 and 5, which are described as “Known RefSeq” by NCBI’s Reference Sequence 
database representing naturally occurring molecules. Therefore, this study focused first 
on the characterization of these reported isoforms in comparison to the isoform 2, which 
is here referred to as “canonical MyD88”. 
 
In comparison to canonical MyD88, isoform 1 has an alternative donor splice site 24 nt 
downstream of exon 3 adding 8 AA upon Lys 227 within the TIR domain, additionally 
exchanging R->G 236, but the TIR domain sequence remains conserved. Isoform 3 skips 
exon 2, isoform 4 skips exon 3 and isoform 5 excludes exons 2 and 3 (Fig.2a). The 
exclusion of exon 3 leads to the deletion of one nucleotide originating a frame-shift, 
which not only alters the amino acid sequence of the protein but introduce a premature 
termination codon (Fig.2a,e). Therefore, I concluded that isoforms 4 and 5 do not have a 
TIR domain. The different AA sequence is shown in Figure 2e and in this study this unique 
sequence will be called as “C-terminal region (CTR)”.  
 
To clone all isoforms, coding sequences (CDS) were extracted from the references 
uploaded in the NCBI nucleotide portal (Fig.2b) and were purchased or synthesized. CDS 
were cloned into expression vectors, which fused a StrepIII-Hemagglutinin-tag (S-HA tag) 
at the N-terminus of the GOI to facilitate track of the proteins, using the gateway system. 
Vector maps are shown in supplementary Figure S1. The AA sequence of all isoforms 
plasmids is schematized in Figure 2c, showing the protein domains they share. 
Furthermore, immunoblotting analysis demonstrated expression and correct size of the 
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isoforms (Fig.2d and MW in Fig.2b). These plasmids have been used in following 
characterization experiments. 
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2 
Isoform 4 
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mRNA Identity  
e 
Figure 2. Generation and description of MyD88 isoforms plasmids. (a) Scheme of MYD88 mRNA in 
gray blocks and coding sequence in colors according to reference sequences listed in (b). Red bar 
represents the death domain (DD), blue bar the intermediate domain (INT) and green the TIR domain.  
The light green bars show the CTR. (b) Detailed information on MyD88 isoforms. (c) Overview of MyD88 
constructs highlighting the conserved domains they share. (d) Protein expression of the generated StrepIII- 
Hemagglutinin (S-HA)-tagged constructs transfected in HEK 293T cells showed by immunoblotting using 
antibodies against the DD of MyD88 and against the HA-tag. (e) Different AA sequence of exon 4 and 5 due 
to exon 3 exclusion in isoform 4 and 5; referred to as CTR. Black squares with an (*) represent a stop 
codon. Illustration done in Geneious Pro 5.5.9. 
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2.3.2 Ability of MyD88 isoforms to activate NF-B  
 
The main function of MyD88-signaling is the activation of transcription factors like NF-B 
to arouse an immune response or/and support survival. Canonical MyD88 overexpression 
has been demonstrated to constitutively activate NF-B in lymphomas (Ceribelli et al. 
2014) and cell lines (Avbelj et al. 2014), shown by an NF-B–dependent dual luciferase 
reporter assay (DLA). Therefore, I used the same assay to evaluate the NF-B activation 
potential of MyD88 alternative isoforms by overexpression in the presence or absence of 
the endogenous MyD88, including all isoforms naturally expressed. Transient transfection 
of MyD88 isoforms in MyD88-deficient HEK 293T cells (known as I3A HEK293 cells, 
described in (Avbelj et al. 2014)) together with luciferase plasmids showed that isoforms 
1, 2 and 4 induced NF-B activation, whereas isoforms 3 and 5 demonstrated loss-of 
function (Fig.3a). To check if the presence of endogenous MyD88 change the activation 
potential of the alternative isoforms, normal HEK 293T cells were used. In this cell line, 
the five isoforms showed the same behavior, but the activation magnitude of isoform 1 
was four times lower than the activation shown in I3A cells, suggesting a reduction of 
potency in the presence of endogenous MyD88 (Fig.3b). But, this last observation needs 
more experiments to be confirm. Moreover, in both cell lines NF- activation was 
dependent on the amount of plasmid transfected. In summary, isoform 1 and 4 can 
induce NF-B activation by themselves, but isoform 3 and 5 not. 
 
Since isoforms 3 and 5 were not able to activate signaling, and according to the literature 
isoform 3 has an inhibitory effect on the MyD88-dependent pathway, I also performed 
experiments to verify this finding. I overexpressed isoforms 3 and 5 in normal HEK 293T 
cells for DLA and stimulated them with flagellin, the ligand known to activate endogenous 
TLR5 in HEK cells. However, no inhibition effect was observed (Fig.S2). From this, I 
concluded that HEK cells may not be the suitable model system to study the inhibitory 
effect of the isoforms, because for isoform 3, it was only observed in innate immune cells. 
 
Isoforms 4 and 5 had remained uncharacterized, because only truncated versions of 
MyD88 containing the DD (Loiarro et al. 2009) and DD-INT (Ceribelli et al. 2014, George et 
al. 2011) had been used to study the function and protein-binding of the canonical 
protein. Thus, the role of the shared CTR of these two isoforms has not been evaluated. 
Therefore, I proceeded to test if this CTR makes a difference in the isoforms functionality. 
For this I compared isoform 4 (Fig.3c) and isoform 5 (Fig.3d) directly with a truncated 
construct expressing MyD88 death domain plus intermediate domain from the canonical 
isoform. As observed in Figure 3c,d a MyD88 truncated version (DD-INT) is able to induce 
NF-B activation like isoform 4, suggesting that the CTR does not influence the function of 
isoform 4. Important to mention is that the truncated version used here has Myc-Protein 
A as fused N-terminal tags and another backbone than the generated constructs, 
therefore we cannot precisely tell the function of the CTR. Thus, as short outlook the 
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generation of an appropriate DD-INT construct could help to assess CTR’s role. Another 
observation is that isoform 5 protein expression is remarkably lower than isoform 4 and 
DD-INT (Fig.3e), suggesting that isoform 5 is not stable and might be degraded faster. 
Nevertheless, even higher amounts of plasmid (100 ng) did not show NF-B activation 
(Fig.S2).  
 
Together, these data suggest that isoform 1 and 4 can contribute to MyD88-dependent 
signaling towards NF-B and propose the DD and INT as the main domains for signaling in 
overexpression conditions. Furthermore, isoform 3 and 5 cannot induce signal.  
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Figure 3. MyD88 isoforms have different phenotypes. (a-d) DLA measurements of NF-B 
activation in (a) MyD88-defient I3A cells and (b-d) HEK 293T cells lysates upon transient transfection 
with MyD88 isoforms or truncated version together with NF-B-inducible firefly luciferase and 
constitutive Renilla luciferase reporter. Cells were lysed 48 h later. Threshold for activation was set at 
5 RLU. (e) Same lysates were used for immunoblotting, where eGFP served as transfection and loading 
control (n=1). Arrow points to isoform 5 corresponding band. Panels (a-d) are representatives of n=3 
showing means+SD of triplicates. EV: empty vector; DD-INT: Death domain-intermediate domain;  
RLU: relative luminescence units; GFP: green fluorescent protein. 
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2.3.3 Physiological existence of MyD88 isoforms in healthy B cells and lymphomas 
 
RNA sequencing data analysis determined the existence of MyD88 alternative splicing. 
Nevertheless, a cell-specific analysis for the presence of each isoform has not been done. 
Here, I chose B cells as a model, because some non-Hodgkin B cell lymphomas are known 
to be addictive to the MyD88-NF-B pathway, which at least in myeloid cells can induce 
MyD88 alternative splicing. Therefore, I hypothesized that the chances to find alternative 
isoforms in B cell lymphomas are high. To test this hypothesis, together with 
collaborators (SH. Bernhart from University Hospital Ulm and R. Siebert from University of 
Leipzig), RNAseq data was analyzed from Burkitt lymphoma (BL), diffuse large B cell 
lymphoma (DLBCL), follicular lymphoma (FL) and FL-DLBCL samples. Because all tested 
lymphomas were derived from germinal center (GC) B cells, isolated GCB cells were also 
investigated. Additionally, naïve B cells were used as controls. To facilitate visualization of 
alternative splicing, RNA sequencing reads were aligned to the human genome and 
Sashimi Plots were generated, where exon reads are converted into density reads (y-axis) 
and splice junctions are represented as arcs (Fig.4a). Then, exon reads from all samples 
were normalized to total RNA amount and aligned to the human MYD88 gene and 
corresponding annotations (Fig.4b). Next, as evidence for the existence of the differential 
isoforms, Sashimi plots of all samples together from naïve B cells, GCB cells and Burkitt 
lymphoma are presented, in which the abundance of splice junction is proportional to the 
width of the arcs (Fig.4c).  
 
Sashimi plots demonstrated canonical MyD88 as the most prominent isoform, since the 
thickest arcs did not skip exons, and start and end at the constitutive splice sites. 
Furthermore, all isoforms except the canonical isoform have unique splice junctions that 
simplify the recognition of each alternative isoform; for example, arc in red represents 
isoform 3 skipping exon 2 (Fig.4c). Then, isoform 1 is represented by an arc starting at an 
alternative donor splice site within the intron after exon 3, isoform 4 by junction skipping 
exon 3 and isoform 5 by junction skipping exon 2 and 3. Interestingly, naïve B cells 
showed a prominent intron retention between exon 3 and 4. According to the signal, 
about half of the MyD88 mRNA transcripts present this intron retention event. This 
finding will be analyzed in detail in Section 2.2.6.  
 
Overall, I concluded all annotated isoforms are expressed at mRNA level in B cell 
lymphomas and control GCB cells and naïve B cells. These isoform-specific junctions 
allowed quantification and deeper analysis of the Sashimi plots, which will be described in 
Figure 6. 
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Figure 4. MyD88 isoforms are naturally occurring in B cells and lymphomas. (a) Figure adapted 
from (Avbelj et al. 2014, Katz et al. 2015), explaining generation of Sashimi plots. (b) RNAseq data 
alignment to the MYD88 gene at hg38 using UCSC genome browser tracks. Normalized data to total 
expression levels (BL, n=21; DLBCL, n=72; FL, n=83; FL-DLBCL, n=14; GC-Bcells, n=5; naïve B cells, n=5). (c) 
Sashimi plots from naïve B cells, GCB cells and solid Burkitt lymphoma showing exon 1-4. Y axis (RPKM) 
represents exon reads and arcs represent exon junctions. The width of the arc is proportional to the 
number of junctions. RPKM: reads per kilobase million. 
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2.3.4 Detection of single MyD88 isoforms mRNA and protein 
 
Upon confirming the physiological expression of the alternative isoforms in B cells, I 
developed a quantification system to assess their expression levels in different 
conditions. The aim was to test their regulation by TLR stimulation. For this purpose, I 
chose DLBCL immortal cell lines from both ABC and GCB types, and primary B cells as 
models of study. First, I designed exon spanning primers to specifically amplify and detect 
single isoforms (Fig.5a). To check if all primers were specific for each isoform I generated 
standard curves and tested each primer pair with all splice variants (Fig.S5). In summary, 
all primer pairs were specific with the exception of the primer pair for isoform 2 that is 
able to detect isoform 1 as well (data not shown). Amplification efficiencies are listed in 
Table 6 and Figure S5. Then, RT-qPCR was performed to determine the expression pattern 
of all alternative isoforms in DLBCL lines and primary B cells. Results showed that 
alternative isoforms are detectable in DLBCL lines but show significantly lower expression 
than primary B cells (p<0.0001). Expression levels of isoforms 4 and 5 were 2 fold and of 
isoform 3 were 2 to 4 fold lower than expression levels of primary B cells (Fig.5b). Thus, 
MyD88 alternative isoforms show lower expression in DLBCL in comparison to healthy B 
cells in a resting state.  
 
Isoform 1 abundance was also tested but the amplicon had a different melting curve than 
the positive control, plasmid DNA encoding the sequence of isoform 1 (Fig.S2a). Because 
of the discrepancy isoform 1 was not included in further experiments. Interestingly, by 
Sanger sequencing I found that the amplicon for isoform 1, isolated from cells, contained 
the intron between exon 3 and 4 (Fig.S2b). At the beginning, this was thought to be a 
contamination of pre-mRNA, but as seen before and described later (Section 2.2.7), the 
observed intron retention is not an artefact, but instead a novel MyD88 isoform (Fig.7).  
 
In addition to the transcription of MyD88 alternative isoforms, I showed by 
immunoblotting that all isoforms are expressed at the protein level. The detection of all 
variants was possible using an anti-MyD88 antibody against a sequence at the beginning 
of the DD, domain that all shared. Immunoblotting showed that the canonical isoform 
was the most abundant, and isoform 4 and 5 the least abundant (Fig.5c). Important to 
mention is that the detection of the alternative isoforms required excessive amounts of 
protein, approximately 50 µg protein per well (commonly used <20 µg). 
 
In summary, I successfully designed primer pairs for the detection and discrimination by 
qPCR of all until now annotated MyD88 isoforms, except for isoform 1. Furthermore, 
besides low expression levels I could showed the expression of the variants at the mRNA 
and protein level. 
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2.3.5 Regulation of MYD88 alternative splicing by TLR stimulation 
 
To reproduce findings from the literature, in which isoform 3 expression is regulated by 
TLR4 activation (Adib-Conquy et al. 2006, Janssens et al. 2003), I stimulated PBMCs with 
LPS, CpG and Pam3CysK4 for 6, 8 and 24 h and measured MyD88 isoform abundance by 
qPCR. Results showed the expected increase of MyD88 isoform 3 upon LPS and CpG 
stimulation. Interestingly, the use of Pam3CysK4 tended to decrease the expression of all 
isoforms (Fig.S3).  
 
Then, to assess if TLR4 signaling modified the expression of the isoforms, DLBCL cells were 
stimulated with LPS for 18 h and whole cell lysates were analyzed by immunoblotting 
with an anti-MyD88 antibody. THP-1 cells were used as controls, because it is a monocyte 
cell line in which isoform 3 according to previous studies is up-regulated upon TLR4 
engagement and because MYD88 KO THP-1 cells are available.  Based on the predicted 
molecular sizes, all isoforms were detected, but no significant differences were found at 
protein level upon stimulation. Surprisingly, THP-1 cells showed also a notable expression 
of isoform 4 in comparison to the DLBCL cell lines (Fig.5c). A possible explanation why I 
could not see differences after LPS stimulation is because the ABC-DLBCL tested cell lines 
have a constitutive activation of NF-B signaling (Ngo et al. 2011), thus LPS alone may not 
cause significant changes in the same downstream pathway and events, such as MyD88 
isoforms expression. On the other hand, GCB-DLBCL cells might be unresponsive to LPS as 
tested in Chronic lymphocytic leukemia, another B-NHL (Jurado-Camino et al. 2015).  
 
Since TLR signaling in B cells is important for antibody production and proliferation, I 
proceeded to assess the abundance of the isoforms during B cell proliferation in vitro. For 
this, I isolated human primary B cells and treated them with CpG plus IgM for 5 days as 
described in Lelis et al. (Lelis et al. 2017). B cells proliferated was successful as observed 
by four different populations in CFSE staining and FACs analysis (Fig.5d). Since we 
observed two populations of B cells we stained cells with CD19, a B cell marker to confirm 
its origin (Fig.5d). RNA was isolated at each day and analyzed for mRNA levels of the 
isoforms by qPCR. Unexpectedly, all MyD88 isoforms were downregulated during B cell 
proliferation. Isoforms showed ~2 down-regulation compared to the unstimulated B cells. 
Although the differences displayed no significance, the trend is obvious (Fig.5e).  
 
Together, this data suggests that B cells reduce MyD88 overall expression and its 
alternative splicing when proliferating. This observation is supported by the comparison 
of isoform abundance between DLBCL lines and primary B cells presented previously and 
by statistical analysis of the RNAseq data described below.     
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Figure 5. Regulation of MYD88 alternative splicing by TLR stimulation. (a) RT-qPCR primer design 
strategy. (b) Relative abundance expression of MyD88 isoform mRNA in DLBCL lines normalized to GAPDH 
compared to healthy B cells (n=1, mean of triplicates); p values from 2way ANOVA test. (c) Expression of 
MyD88 isoforms assessed by anti-MyD88 immunoblot (n=1). (d) CFSE staining showing primary B cell 
proliferation and CD19 staining by FACs analysis; representative of n=3. (e) Relative abundance of isoform 
mRNA in primary B cells upon stimulation with 2,5 µg/ml CpG and 5µg/ml IgM (n=3). Shown mean+SEM 
from n=3. 
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2.3.6 Abundance of MyD88 isoforms in B cell lymphomas compared to healthy B cells 
 
Non-Hodgkin B cell lymphomas are known to 1) overexpress MyD88 (Choi et al. 2013) and 
2) have a high frequency of the hyperactive L265P mutation (Ngo et al. 2011). Both 
scenarios lead to constitutive NF-B activation. I hypothesized that the expression of 
alternative isoforms is increased in B cell lymphomas versus healthy B cells, as observed 
for isoform 3 in monocytes and macrophages upon prolonged TLR4 stimulation, 
theoretically due to constitutive NF-B activation (Adib-Conquy et al. 2006, Burns et al. 
2003). Nevertheless, B cell proliferation in vitro demonstrated down-regulation of the 
isoforms and not the expected increased expression, suggesting that alternative splicing 
might be down-regulated upon prolonged TLR-BCR stimulation (Fig.5e). To extend the 
findings, the abundance of each MyD88 isoform in Non-Hodgkin B cell lymphomas and 
healthy cells was quantified using the RNAseq data presented before. Plotting the relative 
usage of each isoform per group of cells and lymphoma type, isoforms 1, 4 and 5 
displayed significantly less abundance in lymphomas than in naïve B cells (Fig.6a,d,e). 
Isoforms 1, 4 and 5 mRNAs demonstrated to be 1- to 3-fold less than naïve B cells. In 
contrast, canonical MyD88 is 2-fold more expressed by lymphomas than healthy cells 
(Fig.6c) and strikingly, isoform 3 did not show significant differences (Fig.6b). 
Furthermore, GCB cells followed the same trend as naïve B cells using more alternative 
splice junctions, but with less significant data (Fig.6). Of note, no L265P cases were found 
in the tested samples.  
 
Overall, alternative splicing seems to be down-regulated in oncogenic cells with the 
exception of isoform 3. Thus, this data suggests that B cell lymphomas use constitutive 
splice sites over the alternative sites. B cell lymphomas might then down-regulate 
alternative splicing to produce higher levels of canonical MyD88, which showed the 
highest activation of the pro-survival factor NF-B. Furthermore, the stable abundance of 
isoform 3 implies a separate regulation for expression. 
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Figure 6. MyD88 alternative isoforms are downregulated in B cell lymphomas.  
Isoform quantification by relative abundance taking unique splice sites or junctions for each 
isoform: (a) exon3+20nt to exon4 = Isoform 1; (b) exon1 to exon3 = Isoform 3; (d) exon2 to 
exon4 = Isoform 4 and (e) exon1 to exon4 = Isoform 5. (c) Isoform 2 abundance = 1- 
ΣIsoforms\isoform2 abundance. Wilcoxon Mann-Whitney test was applied for statistical 
significance. Box-Whiskers plots and statistics were made by SH. Bernhart (University of 
Leipzig). BL, n=21; DLBCL, n=72; FL, n=83; FL-DLBCL, n=14; GCBcells, n=5; Bcells, n=5.  
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2.3.7 Discovery of novel isoforms  
 
The initial RNAseq analysis by splice mapping revealed the presence of at least 2 novel 
isoforms. The most prominent newly discovered alternative splicing event is an intron 
retention between exon 3 and 4 (Fig.8a), event that generates a distinct splice variant 
with a truncated TIR-domain, here called isoform 6 (Fig.7 and Fig.8b). Furthermore, we 
found a novel splice site 20 nt upstream of the canonical donor site from exon 3, having a 
Human Splicing Finder score (HSF) of 81 (Desmet et al. 2009), creating isoform 7 (Fig.8a).  
A HSF score above 65 is consider a strong splice site. For isoform 7, two predicted 
sequences exist in GeneBank: 7.1 uses just the novel splice site and 7.2 additionally skips 
exon 2 (Fig.7 and Fig.8b). The use of this novel donor site shift the AA frame and causes 
an early stop codon and translates the exact C-terminal region determined for isoform 4 
and 5 (Fig.7 and Fig.2e). Thus, the discovered splice events generate more truncated 
versions of MyD88. Since they have an intact DD-INT structure, they fulfill the 
requirements to transmit signal.  
 
It is important to mention that intron retention is one of the rarest events of alternative 
splicing and often neglected, because these events may originate from contamination of 
pre-mRNA molecules (Ge and Porse 2014). Nevertheless, the intron retention observed 
here covers almost 50% of the total MyD88 transcripts, suggesting that the existence of 
the corresponding isoform is intentional.  
 
Regarding the usage of the novel alternative splice sites, healthy B cells again showed a 
higher abundance than B cell lymphomas (Fig.8c,d). Thus, these final outcomes support 
the idea that lymphomas prefer the expression of the canonical MyD88 over the 
alternative and mainly truncated isoforms.  Nevertheless, their function evaluation would 
be of high interest.   
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Figure 7. Illustration of isoforms 6 and 7 in comparison to the canonical MyD88 isoform.  (a) Illustration of intron retention between exon 3 and 4 in 
isoform 6. Zoom in to show translation of intron retention which adds a premature stop codon. (b) Illustration of alternative splice site within exon 3 causing a 
frameshift in the AA sequence and therefore a premature stop codon. The translation of exon 4 correspond to the here called CTR. Pictures generated in Genious  
Pro 5.5.9. Big colored squares show AA sequence and black square with an (*) represent a stop codon. 
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Figure 8. Discovery of novel isoforms. (a) Sashimi plot from naïve B cells showing intron retention 
and the novel spice site. (b) Scaled scheme of MyD88 mRNA in gray blocks and coding sequence in 
colors according to domain sequences if available. Light green block represents CTR. (c-d) Isoform 
quantification by relative abundance taking unique splice sites for each isoform: (c) Novel site 
upstream of canonical donor within exon3 and (d) exon4 acceptor site. Wilcoxon Mann-Whitney test 
was applied for statistical significance. (c,d) Box-Whiskers plots and statistics made by SH. Bernhart 
(University of Leipzig). BL, n=21; DLBCL, n=72; FL, n=83; FL-DLBCL, n=14; GC-Bcells, n=5;  
naïve B cells, n=5.  
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2.3.8 Mutated MyD88 isoforms  
 
As preliminary data, I tested if the somatic mutation c.794T>C (p.L265P) could influence 
the phenotype of alternative isoforms as previously shown with isoform 2 (Avbelj et al. 
2014). Interestingly, mutated isoform 4 showed hyperactivity at low plasmid 
concentrations similar to canonical MyD88 (See arrows Fig.9a,b). However, other splice 
variants showed no different phenotype (Fig.9a,b). Last, the T>C exchange disrupts the 
original stop codon in isoforms 4 and 5 adding 8 extra AA. Thus, these extra AA could 
attribute the hyperactivity of isoform 4 (Fig.9c).  Overall, this data confirms that Myd88 
isoform 2 and suggests isoform 4 become hyperactive when introducing the 
corresponding L265P mutation.  
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Figure 9. Myd88 isoforms 2 and 4 become hyperactive with the corresponding L265P 
mutation. (a,b) DLA measurements of NF-B activation in (a) MyD88-defient I3A cells lysates or (b) 
HEK 293T cells lysates upon transient transfection with MyD88 isoforms in WT and mutated versions 
together with NF-B-inducible firefly luciferase and constitutive Renilla luciferase reporter. Cells were 
lysed 48 h post transfection. Panels are representatives of n=3 showing means+SD of triplicates. (c) 
Addition of AA due to somatic mutation c.794T>C on exon 5 disrupts the original stop codon in isoforms 
4 and 5. Big colored squares show AA sequence and black square with an (*) represents a stop codon. 
Illustration generated in Geneious Pro 5.5.9. RLU=relative luminescence units. 
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2.4. Discussion 
 
MyD88 alternative splicing and its function have been little studied. To date, only isoform 
3 was investigated and suggested to be a negative regulator of the MyD88 pathway in 
humans and mice. In general, alternative splicing has been implicated and shown to occur 
frequently in human cancer (Wang et al. 2015), but it is less well understood which 
alternative splice isoforms could contribute to the malignant state of the cells. Therefore, 
for MyD88, I first characterized its four alternative isoforms found in transcriptome 
analysis together with the canonical isoform. In luciferase reporter assays, two out of the 
four alternative isoforms (1 and 4), whose protein structure shared complete DD and INT 
domains, were able to induce NF-B activity. These results were expected as truncated 
versions of canonical MyD88, designed as DD plus INT, were shown to be sufficient to 
transmit signal (George et al. 2011). On the other hand, constructs with separated 
domains, namely DD, INT and TIR alone were suggested to not induce, but instead inhibit 
the pathway (Loiarro et al. 2009, Avbelj, Horvat, and Jerala 2011, Fekonja, Bencina, and 
Jerala 2012). In my studies, I could only see the loss-of-function of isoform 5, which 
consists of the DD alone plus a CTR. However, the loss-of-function could also be due to a 
high mRNA or protein instability, as evidenced by the low signal in immunoblots. A 
possible explanation might be that its degradation is a result from the function of an 
mRNA surveillance pathway named nonsense-mediated mRNA system, which deals with 
transcripts with premature termination codons. This system commonly prevents the 
expression of C-terminal truncated proteins that could potentially have dominant 
negative properties (Ge and Porse 2014), as would be the case for isoform 5.  
  
Previous studies also found that isoform 3 showed a loss-of-function and dominant 
negative effect on MyD88 signaling by overexpression in HEK cells and recurrent 
stimulation of macrophages, respectively (Avbelj, Horvat, and Jerala 2011, Adib-Conquy 
et al. 2006, Janssens et al. 2003). These properties were attributed to its lacking the INT, 
because this domain was reported to support MyD88 conformational changes critical to 
signal transmission (Avbelj, Horvat, and Jerala 2011). To assess the inhibitory effect of 
isoform 3 and potentially of isoform 5, I performed several experiments using the DLA 
system in flagellin-stimulated HEK cells, but I could not see suppression of TLR5 signaling 
by overexpression of the isoforms. As isoform 3 inhibitory effect has been only shown in 
macrophages, bronchial epithelial cells and fibroblast, I consider the effect could not be 
seen here, because it has been shown in innate immune cells, but not in other cells e.g. 
HEK cells. Furthermore, the negative regulation has been exclusively shown for TLR2 and 
TLR4 signaling (Andrews et al. 2016, Burns et al. 2003, Adib-Conquy et al. 2006). Thus, to 
gain knowledge about isoform 3 and 5, it will be interesting to overexpress them in B cells 
and check its function. TLR2 stimulation, together with isoforms overexpression in B cells 
would be also of high interest to assess the restrictedness of the negative effect to this 
TLR and rule out cell-specific effects. Also, TLR2 stimulation is often used, besides TLR9, to 
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induce B cell proliferation with BCR co-stimulation (Ganley-Leal, Liu, and Wetzler 2006, 
Bekeredjian-Ding and Jego 2009, Bekeredjian-Ding et al. 2007). Thus, in general, these 
conditions are a good system to further study all isoforms’ function in B cells.  
 
Next, based on knowledge from the literature that MyD88 overexpression and the 
hyperactive mutation L265P lead to a constitutive activation of NF-B in B cell lymphomas 
and that isoform 3 expression is inducible by prolonged TLR stimulation (presumably via 
NF-B), I hypothesized that B cell lymphomas addicted to NF-B signaling (e.g. FL and 
ABC-DLBCL (Ngo et al. 2011, Suzuki et al. 2010)) would have higher expression of MyD88 
alternative isoforms than other lymphomas (e.g. Burkitt lymphoma and GCB-DLBCL) and 
healthy B cells. Additionally, the hypothetically increased expression of the alternative 
isoforms and the ability of isoforms 1 and 4 to transduce signal could support the 
proposal that the alternative isoforms contribute to the activation of the pro-survival 
transcription factor. To test these hypotheses, I started evaluating possible regulatory 
conditions of MyD88 isoforms expression using CD19+ primary B cells as a healthy control 
and DLBCL cell lines as oncogenic samples. Overall, I could show the expression of the 
alternative isoforms at mRNA and protein level and interestingly the abundance of the 
alternative isoforms was lower in the DLBCL lines versus primary B cells. Additionally, 
primary B cells under proliferative conditions reduced the expression of all MyD88 
isoforms. Together, both observations turned out to be the opposite of my hypothesis.  
 
The latter finding, low MyD88 levels during proliferation, even of the canonical isoform, 
could be explained by a B cell subtype-specific issue. In this study, I stimulated peripheral 
B cells with a TLR9 and B cell receptor (BCR) agonist to mimic conditions of a B cell 
entering the germinal center where proliferation (Lelis et al. 2017), class-switching and 
differentiation to plasma cells in a T-independent manner happens, theoretically events 
dependent on MyD88 overexpression (Hua and Hou 2013, Rawlings et al. 2012). 
However, MyD88 overexpression has been observed in follicular B cells entering the 
germinal center, and it has not yet been measured in other B cell subtypes such as 
peripheral B cells under conditions of stimulation. Moreover, extrafollicular B cells are 
suggested to need a TACI-MyD88 signaling for germinal center events (He et al. 2010, 
Rawlings et al. 2012). Together, this could indicate that I observed a general down-
regulation of MyD88 transcription during primary B cell proliferation because I used 
different stimuli and another subtype of cells. Thus, it will be worth to test the TACI-
MyD88 signaling instead of the TLR9-MyD88-BCR signaling to assess the expression levels 
of MyD88 isoforms and clarify the discrepancy of total expression.  
 
Furthermore, since DLBCL cell lines showed less expression of alternative isoforms than 
primary B cells in RT-qPCR analysis, together with collaborators I did a deep RNAseq data 
analysis of BL, FL, DLBCL and GCB-DLBCL samples, and germinal center and naïve B cells as 
controls, to have clearer results regarding my hypothesis. Data showed the natural 
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occurrence of the 5 previously described MyD88 isoforms and gave convincing evidence 
for the existence of 2 additional alternative isoforms (isoform 6 and 7). Isoform 2 
exhibited higher mRNA levels (overexpression) in lymphomas than in healthy cells as 
expected and previous shown (Mudaliar et al. 2013, Choi et al. 2013). Nevertheless, the 
abundance of the alternative isoforms was in general lower in B-NHL than in healthy B 
cells, except for one isoform (isoform 3). To understand better these outcomes, I will 
discuss first how alternative splicing can be regulated.  
 
Alternative splicing is a process by which defined “alternative” splice sites are preferred 
to canonical splice sites. This process can either occur constitutively or under regulatory 
conditions, which can be dependent on cellular stimulation or cell type. For example, 
MyD88 isoform 3 expression can be increased by stimulating innate immune cells with 
TLR ligands, whereas fibroblast growth factor receptor-2 (FGFR2) is an example for cell 
type-specific expression, in which one of two different isoforms is expressed in either 
epithelial cells (FGFR2-IIIb) or mesenchymal cells (FGFR2-IIIc) (Wagner et al. 2003, 
Kozlovski et al. 2017). Thus, stringent regulation of alternative splicing is crucial for the 
complex requirements of tissue- or signaling-dependent splicing under normal conditions. 
However, alternative splicing in oncogenesis is frequently manipulated leading to 
aberrant splicing (Sveen et al. 2016). A recent example is the expression of alternative 
isoforms, ,  and , in breast cancer of the protein DMTF1 (Tian et al. 2017, Maglic et al. 
2015), which isoform b induce strong proliferation and progression of the cancer cells.  
 
There are a wide variety of causes of alterations in the splicing process, but here I will 
discuss the most common ones. One cause is direct aberrations in splice factors, which 
can be alterations of their abundance, localization and activity. The most common 
example is the overexpression in many cancers of the oncogene MYC. MYC controls 
transcription of multiple splicing factors resulting in aberrant splicing of numerous genes 
related to lymphomagenesis discovered and reviewed by Koh and colleagues (Koh et al. 
2015). Interestingly, MyD88 was not listed. Mutations in splice factors are less frequent, 
but have been seen in e.g. the spliceosome member SF3B1 appearing in breast cancer, 
melanoma and chronic lymphocytic leukemia (Alsafadi et al. 2016, Singh and Eyras 2017, 
Wan and Wu 2013). One of the frequent SF3B1 mutations is p.K700E, which has been 
proved to cause aberrant splicing (Obeng et al. 2016, Inoue and Abdel-Wahab 2016) and 
loss-of function (Darman et al. 2015, Wang et al. 2016). Strikingly, SF3A1 or SF3B1 knock 
down, mimicking loss of function, has showed to induce MyD88 isoform 3 expression in 
murine macrophages, as published by De Arras et al. (De Arras and Alper 2013). 
Therefore, the authors proposed SF3A1/SF3B1 as regulatory candidates for MyD88 
alternative splicing, though they only investigated isoform 3. Despite SF3B1 mutations 
have been discovered in chronic lymphocytic leukemia (Wang et al. 2016, Wan and Wu 
2013, Wu, Tschumper, and Jelinek 2013), which is also a B-NHL, there is no evidence that 
this mutation occurs in the tested B-NHLs. The second most common manipulation of 
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alternative splicing are polymorphisms within the affected gene. Mutations can occur in 
splicing enhancer/silencer elements or create new splice sites (Tazi, Bakkour, and Stamm 
2009). Most of the splice site mutations that lead to human disease happen at the GT and 
AG dinucleotides in the 5’ and 3’ canonical splice sites, essential sites for exon definition. 
Thus, mutations at these positions result in exon skipping, activation of a cryptic splice 
site, or intron retention (Ward and Cooper 2010). However, in the case of MyD88, 
alternative splicing events occur in healthy B cells and seem not to be products of 
aberrations. Thus, considering all the mentioned causes of aberrant alternative splicing 
found in oncogenesis and the main finding that MyD88 alternative splicing is 
downregulated in B cell lymphomas, I conclude that MyD88 alternative splicing occurs 
under normal conditions and it is not a consequence of oncogenesis or NF-B constitutive 
activation as hypothesized. 
 
My study showed that alternative isoforms 1 and 4 induce NF-B activation and based on 
the protein sequence of isoform 6 and 7.1 I speculate that they might too. However, why 
are alternative isoforms downregulated in B cell lymphomas, although the majority is able 
to induce signaling via NF-B? The data presented in this thesis indicates that lymphomas 
prefer the expression of the canonical MyD88 over the alternative isoforms. All 
alternative MyD88 isoforms are truncated versions of the canonical version (with the 
exception of isoform 1) and they all showed less activation potential for NF-B than 
canonical MyD88. Together, this suggests that lymphomas suppress alternative splicing in 
order to produce the most potent isoform, canonical MyD88, which has been confirmed 
many times to contribute to oncogenesis; for example MyD88 overexpression was 
associated with worst prognosis, tumor recurrence and shortened disease-free survival in 
DLBCL cases (Reddy et al. 2017, Choi et al. 2013). Hence, one imaginable role of the 
MyD88 alternative splicing is to counterbalance the potency of the canonical isoform. 
This idea is supported by the discovery of Rhyasen et al. and unpublished findings by 
Smith et al., in which another important member of the TLR pathway, IRAK4, was found 
to express a cancer-specific isoform in myelodysplastic syndrome (MDS) developed to 
acute myeloid leukemia (AML) (Rhyasen et al. 2013). This isoform lacks the N-terminal 
death domain, important for the interaction with MyD88 and IRAK1 (see Figure 1) but 
showed the ability to induce innate immune signaling. Nevertheless, Smith et al. found 
that MDS/AML samples predominantly express the canonical IRAK4 protein, while normal 
hematopoietic bone marrow cells express the truncated IRAK4. Moreover, they 
demonstrated that canonical IRAK4 expression is significantly associated with increased 
NF-B activity and correlates with poor AML patient outcome (Smith et al. 2016). Thus, 
alternative splicing of MyD88 and IRAK4 seem to be downregulated by cancer in order to 
express the canonical isoforms, being the most potent variants. To support this idea, I 
performed a pilot analysis of RNAseq data from ovarian cancer samples. Similar to B cell 
lymphomas, MyD88 overexpression is known to exert an oncogenic effect by inducing 
constitutive NF-B activation in ovarian cancer (Annunziata et al. 2010). Furthermore, it 
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has been demonstrated that NF-B plays a role in the propagation and poor outcome of 
ovarian cancer (Annunziata et al. 2010, Alvero 2010). Preliminary analyses showed the 
existence of the MyD88 splice variants in ovarian cancer samples, as well as the novel 
isoforms (Fig.S6). But, further analysis concerning the abundance of MyD88 isoforms in 
comparison to healthy ovarian cells remain to be done. 
 
Regarding isoform 3, surprisingly it showed no significant differences between the groups 
and remained similar in healthy and oncogenic conditions of B cells. Thus, its expression 
trend implies that this isoform might be regulated separately from the other splice 
variants. The fact that isoform 3 is the only one lacking the intermediate domain and 
described to have an inhibitory function, makes it very likely that its regulation is 
different. For example, its expression could be independent of the NF-B pathway or 
regulated by distinct splicing factors as shown by SF3B1 knock down (De Arras and Alper 
2013). Nevertheless, I cannot rule out the possibility of a different regulation of the 
isoform between myeloid cells and lymphocytes, because this study is the first to assess 
MyD88 alternative splicing in B cells and TLR stimulation showed downregulation of 
MyD88 total transcription. Its inhibitory effect plays a critical role in acute responses, 
since it has been linked to tolerance of TLR2 and TLR4 re-stimulation upon septic 
conditions in human monocytes (Adib-Conquy et al. 2006); but has not been investigated 
so far in oncogenesis. Thus, the regulation of MyD88 isoform 3 in oncogenesis will be of 
high interest since its inducible overexpression could be a potent and natural inhibitor of 
the MyD88-dependent pathway in the corresponding MyD88-driven B cell lymphomas.  
 
Collectively, MyD88 alternative splicing is not an oncogenic cause and MyD88 alternative 
isoforms do not seem to have an oncogenic role at least in the B cell lymphomas tested in 
this study. Instead I propose that MyD88 alternative isoforms may play important roles in 
the broad functions of MyD88 in B cells (presumably before entering the germinal center 
or other stages) or in other cell types.   
 
Focusing on the fast and high dynamic assembly and disassembly of the Myddosome it is 
likely that the alternative isoforms can support Myddosome formation.  Recently, it was 
published by Bryant and colleagues that upon activation, TLR4/MD2 only forms dimers 
and not oligomers to nucleate the assembly of the Myddosome, demonstrating a 
stoichiometric mismatch between the receptor and the huge complex (Latty et al. 2018). 
As determined by the crystal structure the Myddosome contains six MyD88 death 
domains (Lin, Lo, and Wu 2010). Thus, TLR4 has just a transient role in the nucleating 
assembly (Latty et al. 2018). MyD88 alternative isoforms 1, 4, 6 and 7 can transmit signal, 
and interestingly isoform 6 has a truncated TIR domain and isoforms 4 and 7 do not have 
this domain. Because the TIR domain comprises the biggest portion of the MyD88 
molecule, one could assume that the truncated isoforms (4,6 and 7) could have a steric 
advantage in the complex, needing less space as the canonical MyD88 and conferring 
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more structural flexibility to the complex. The latter publication indicated that only two 
TIR domains are needed for the nucleation of the Myddosome (Latty et al. 2018), thus 
theoretically also only 2 canonical MyD88 molecules are enough for the nucleation, 
opening the possibility to truncated versions to complete the complex, since the MyD88 
scaffold contains six MyD88 death domains (Lin, Lo, and Wu 2010) and all alternative 
isoforms have this domain. Additionally, defined truncated versions of the canonical 
MyD88 were used to study MyD88’s function and interactions with other members of the 
TLR-MyD88 cascade. For example, TACI was shown to bind to MyD88 in a TIR- 
independent manner in B cells (He et al. 2010). Thus, truncated isoforms could also 
mediate specific MyD88-interactions to other molecules and/or therefore induce 
signaling of transcription factors, apart from NF-B, as determined by canonical MyD88 
(e.g. CREB, AP-1) (Gay et al. 2014).  
 
 
 
2.5 Conclusion  
 
MyD88 has been associated to many different cancer types, specially to non-Hodgkin 
lymphomas due to overexpression and the somatic mutation L265P. These aberrations 
lead to a constitutive NF-B signaling, which mediates cell survival, proliferation and 
maintenance of the tumor environment. Furthermore, assuming from the literature that 
the expression of the MyD88 alternative isoform 3 can be induced by acute TLR-signaling, 
e.g. during sepsis, theoretically in a NF-B-dependent manner; I hypothesized that B cell 
lymphomas addictive to NF-B signaling would have higher levels of alternative splicing 
than healthy B cells. Moreover, the alternative isoforms could support the oncogenic 
effect of MyD88. This study is the first to prove the existence of all until now annotated 
MyD88 isoforms, plus two novel isoforms, in primary B cells and Non-Hodgkin B cell 
lymphomas at the mRNA and protein level. I also showed that potentially four out of the 
six MyD88 variants are functional. And although the alternative isoforms did not show 
relevance for oncogenesis, at least in B cells, they suggest having a functional role in 
healthy cells, where they were highly expressed. I speculate that MyD88 alternative 
isoforms could participate in the Myddosome formation, signal transmission and extend 
protein-interactions of canonical MyD88. Thus, alternative isoforms warrant further 
investigation assessing their potential roles in the Myddosome assembly and the 
regulation of alternative splicing process as a mechanism to attenuate the oncogenic 
potency of canonical MyD88. 
 
 
 
 
 
 38 
Chapter 3: Assessing Chitin-TLR2 interaction in mammals 
3.1 Introduction 
 
Chitin is the second most abundant polysaccharide in nature, having a vital role in the 
structural stiffness of cell walls present in exoskeleton of arthropods, the egg-shell of 
nematodes and the cell wall of fungi. Unlike other oligosaccharides, chitin has been 
described as a strong immunogenic ligand relevant in fungal infections and as an allergen 
associated with allergic asthma in humans (Brown et al. 2012, To et al. 2012). 
Additionally, although different receptors have been hypothesized to recognize chitin and 
mediate its multiple pathological effects, depth molecular studies describing how chitin is 
sensed by a receptor in innate immune cells are required (Bueter, Specht, and Levitz 
2013). 
 
3.1.1 Chitin properties and metabolism  
 
Chitin is a linear homopolymer of β-(1,4)-linked N-acetyl-D glucosamine (GlcNAc) 
monomers, able to form stable microfibrils that, together with glycoproteins and  
(1,3)-glucan chains, constitute the structural basis of hard cell walls from living beings. 
Of interest is that chitin is a component of fungal cell wall (Munro and Gow 2001). Chitin 
requires a complex synthesis process including seven classes of chitin synthase enzymes 
in fungi. Although they have shown to be redundant, their expression can vary among 
fungal strains and suggests being tightly regulated (Pacheco-Arjona and Ramirez-Prado 
2014). The expression and activity of chitin synthases change throughout the fungal cell 
cycle and under stress conditions. For example, in response to lytic enzymes or oxidants 
within phagolysosomes of innate immune cells, chitin synthases are overexpressed to 
restore fungus cell integrity. Furthermore, transcriptional activation of synthases may be 
clinically relevant since it is a protection mechanism against antibiotics and anti-fungal 
drugs through thickening of the fungal cell wall (Lee et al. 2008, Lenardon, Munro, and 
Gow 2010). 
 
Besides its presence in human disease vectors, like insects, and infectious pathogens, 
chitin alone has been determined to elicit a strong immunogenic response as an allergen 
and as a MAMP (Reese et al. 2007, Lee et al. 2008, Lenardon, Munro, and Gow 2010, Choi 
et al. 2016). Chitin is sensed by a large array of immune cells such as macrophages and 
eosinophils, or stromal cells like epithelial cells and keratinocytes evoking inflammation 
and allergy, reviewed in (Elieh Ali Komi, Sharma, and Dela Cruz 2017). Thus, to overcome 
chitin’s pathogenicity, mammals have developed mechanisms to degrade it.  
 
Mammals and bacteria can catabolize chitin. Chitin polymers catabolism is mediated by 
chitinases, e.g. human Chitotriosidase, and chitinase-like proteins e.g. breast regression 
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protein (BRP)-39/YKL-40 (Lee et al. 2011), which degrade chitin in two steps: 1) initial 
hydrolysis generating chitin oligosaccharides and 2) further break down of glycosidic 
bonds to dimers or monomers (Elieh Ali Komi, Sharma, and Dela Cruz 2017).  Bacteria and 
fungi use chitinases to recycle the saccharides (Bueter, Specht, and Levitz 2013). 
Important in this project are two main groups of chitinases: endochitinases and exo-
chitinases. Endochitinases randomly hydrolyze chitin at internal sites generating low 
molecular mass multimers such as chitotriose and chitotetraose or longer oligomers. On 
the other hand, exo-chitinases catalysis starts at the non-reducing end, breaking the 
oligomeric products of endochitinases, thereby generating GlcNAc monomers (Hamid et 
al. 2013). Incidentally, we and others (Kuusk, Sorlie, and Valjamae 2017) propose that 
chitinases, specially endochitinases, could degrade microbe-derived chitin-containing 
structures and once released, oligosaccharides could subsequently trigger an immune 
response. Furthermore, dysregulation in the expression, mainly increased levels, of 
chitinases and chitin-like proteins has been linked to inflammatory and allergic conditions 
such as inflammatory bowel disease and asthma (Lee et al. 2011). Therefore, in this 
project we aimed to assess the induction of chitin-dependent innate immunity triggered 
by chitin oligomers from 4 to 15 GlcNAc. 
 
 
3.1.2 Chitin immune responses in mammals 
 
In mammals, recent studies have suggested that several PRRs are responsible to regulate 
chitin-dependent immune responses: 1) Da Silva and colleagues (Da Silva et al. 2009) 
found that in macrophages, the CLRs mannose receptor and Dectin-1 trigger the 
production of TNFα and IL-10 in response to chitin. Additionally, 2) Da Silva et al. (Da Silva 
et al. 2008, Da Silva et al. 2009) also showed that TLR2 can mediate chitin-responses 
inducing expression of TNFα, IL-10, IL-17A and IL-17AR expression. 3) Wagener et al. 
(Wagener et al. 2014) using corresponding knockout mice, showed that upon chitin 
recognition, TLR9, a toll-like receptor member, and NOD2, a nucleotide-binding 
oligomerization domain-like receptor member, both down-regulate the chitin-mediated 
inflammation by producing the anti-inflammatory cytokine IL-10. 4) Mora-Montes et al. 
(Mora-Montes et al. 2011) demonstrated that chitin can block the recognition of 
immunogenic β-glucans on fungal pathogens by Dectin-1, a member of the C-type-lectin-
like receptors. And 5) further CLRs like Mincle and mannose receptor (Wagener et al. 
2014, Kottom et al. 2017, Shibata, Metzger, and Myrvik 1997) have been also suggested 
to sense chitin, but with high controversy. 
 
Yet, even though the above-mentioned receptors have been associated to chitin-immune 
responses, the exact molecular mechanisms behind the immune response were not 
elucidated and the direct binding to chitin was not validated. Thus, the responsible 
receptor for the immunological effects of chitin remains elusive. Furthermore, 
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contaminants in used chitin preparations cannot be excluded and could be responsible 
for the immunogenic effects measured. One possible explanation for the lack of 
validation experiments can be chitin’s highly polymeric structure. Chitin preparations in 
the publications cited above are 1-40 µm large, containing thousands of GlcNAc 
monomers (Fuchs et al. 2018). Such dimensions make it difficult to assess the chitin-
receptor interaction at the molecular level, since a typical ectodomain size of a receptor is 
in average 8 nm (Gutmann et al. 2018). Moreover, chitin polymers are insoluble and 
therefore difficult to purify. On the other hand, chitin oligomers have been used to define 
the multimeric CEBiP/Cerk1 chitin receptor, as part of the plant innate immune response 
against fungal chitin (Miya et al. 2007, Liu et al. 2012). Furthermore, Schlosser et al. 
(Schlosser et al. 2009), discovered FIBDC1 as a mammalian chitin-receptor, found highly 
expressed in enterocytes of the gastrointestinal tract, using also chitin oligomers. 
However, this latter recognition has not been associated to an immune response so far. 
 
Thus, here we proposed to use defined-size chitin oligomers to assess chitin-receptor 
interaction and the resulting immune response.  
 
 
 3.1.2 Toll-like receptor 2  
 
Toll-like receptor 2 is a special TLR because it increases the variety of its ligands by 
forming heterodimers with TLR1, TLR6 and possibly TLR10. These TLRs are proposed to be 
unable to induce signal in the absence of TLR2, and likewise TLR2 is probably unable to 
signal without a co-receptor. TLR2 and TLR1 together identify triacylated lipopeptides, 
and TLR2 with TLR6 diacylated lipopeptides (Gay et al. 2014). Both lipopeptides are 
components from the cell-wall of Gram-positive and Gram-negative bacteria, and 
mycoplasma (Takeuchi et al. 2001). Thus, synthetic ligands are commonly used to engage 
each specific dimer, for TLR2/TLR1: Pam3CSK4 is used and for TLR2/TLR6: Pam2CSK4, FSL-
1 and MALP-2 are used. FSL-1 and MALP-2 are synthetic diacylated lipopeptides derived 
from Mycoplasma salivarium and Mycoplasma fermentans, respectively (Shibata et al. 
2000, Takeuchi et al. 2001). Not long ago, TLR10 has been shown to also dimerize with 
TLR2 evoking an anti-inflammatory response (Oosting et al. 2014). All TLR2 heterodimers 
have been proven to signal primarily in a MyD88-dependent manner; nevertheless Nilsen 
et al. revealed that these heterodimers can be internalized towards early endosomes, 
where they can signal via the TRAM/TRIF-pathway inducing the production of IFN-
andCCL4 (chemokine C-C-motif ligand 4). Additionally, in the endosomal compartment, 
they can induce production of CCL5 involving the kinase TBK1 and transcription factor 
IRF3, as well as MyD88 (Nilsen et al. 2015). Interestingly, the engagement of a 
TLR2/TLR10 dimer apparently fails to induce a typical pro-inflammatory response but 
rather inhibits the production of inflammatory cytokines like IL-6 and IFN-Of note 
TLR10 ligand remains elusive. Therefore, authors used an anti-TLR10 antibody to induce 
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signal. The dimer suppresses both MyD88-dependent and independent signaling(Hess et 
al. 2017, Oosting et al. 2014, Jiang et al. 2016)suggesting a regulating function.  
 
Recently, CD14 and CD36 have been described as accessory molecules facilitating TLR2 
responses, where CD36 binds lipopeptides and transfers them to CD14, which 
subsequently transfers the ligand to the TLR2 heterodimer. The proposed role of this 
accessory molecules is to diminish the threshold needed to activate receptor signaling 
(Oliveira-Nascimento, Massari, and Wetzler 2012).  
Besides recognizing bacterial lipopeptides, TLR2 recognizes structures in the fungal cell 
wall. It senses phospholipomannans and β-mannoside chains in combination with 
galectin-3 (Choteau et al. 2017). Moreover, TLR2-dependent responses have been 
associated to lung inflammation upon inhalation of fungi and yeasts, and intestinal 
inflammation due to e.g. Candida albicans infection and treatments with zymosan 
(Choteau et al. 2017, Sato et al. 2003, Taylor, Richmond, and Upham 2006). Additionally, 
murine fungal infection models have demonstrated TLR2 as a key receptor for pathogenic 
fungi including: Aspergillus fumigatus, Aspergillus niger, Cryptococcus neoformans among 
others (Goodridge and Underhill 2008). 
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Fig.M.1a,b from manuscript. 
Electron micrograph of a human 
macrophage engulfing a crude 
chitin particle; size comparison of 
typical TLR ectodomain and seven 
NAG subunits. 
3.2 Hypothesis and aims 
 
Studies of the chitin recognition by the immune system are relevant for therapeutic 
strategies against fungal infections like candidiasis, as well as arthropod related allergies 
for example to house dust mite allergens. Previous studies aiming to find the chitin-
receptor in mammals have used chitin macroparticles with variable purity. Thus, the 
overall project aimed to validate the binding to suggested receptors or find a novel chitin-
receptor using highly pure chitin oligomers, which would match the size of a receptor’s 
ectodomain. 
To illustrate the challenge of studying the interaction 
between chitin and its receptor at a molecular level, we 
conducted electron microscopy studies of a macrophage 
incubated with the type of chitin preparation used in the 
literature, where we observed that chitin particles can be as 
big as cells. Thus, chitin oligomers would have more suitable 
dimensions to solve molecular chitin recognition, as shown 
with the schematic of a TLR ectodomain (ECD).   
 
This thesis project is part of the findings described in a 
manuscript Fuchs, Cardona Gloria, 2018 with the title: The 
fungal ligand chitin directly binds and signals inflammation 
dependent on oligomer size and TLR2. My direct 
contribution to this manuscript was to confirm the found 
TLR2 as a chitin-receptor, to evaluate other receptors 
suggested by the literature and explore the chitin binding 
site in TLR2. Furthermore, a preliminary analysis of the 
involvement of TLR2 co-receptor was performed.  
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3.3 Results 
  
3.3.1 Background findings in Manuscript  
 
Although different receptors have been suggested to mediate the pleiotropic 
immunogenic effects of chitin, molecular studies to prove receptor interaction to chitin 
remain elusive. So far, chitin preparations were mainly obtained by extraction from 
shrimp and crab shells or fungal cell wall preparations, with a great variation in molecular 
size and purity.  
 
We then first tested the immunogenic properties of chitin oligomers comprising 4 to 15 
NAGs (N-acetyl-glucosamine). Results showed that oligomers ≥6 NAGs elicited pro-
inflammatory cytokines in human and murine macrophages. The oligomer size with the 
highest immunogenic potency was a mixture of 10-15 NAGs, referred here as C10-15 
(experiments done by K. Fuchs). C10-15 was able to induce secretion of pro-inflammatory 
cytokines from several primary immune cells, such as monocytes, macrophages and 
neutrophils (experiments done by other authors). Thus, this mixture was used to assess 
the chitin-receptor. 
 
The following sections summarize my individual contribution to the “Fuchs, Cardona 
Gloria, 2018 manuscript” (Fuchs et al. 2018), supported by experiments from other 
authors. 
  
 
3.3.2 Chitin 10-15 oligomer induce a TLR2-dependent immune response 
 
To identify the chitin-receptor we used murine bone marrow-derived macrophages 
(BMDMs) from several strains of KO mice and stimulated them with C10-15 and 
respective control ligands. As outcome of a chitin-dependent immune response, we 
measured TNF- levels in the cell supernatants. Myd88 and Tlr2 KO BMDMs showed a 
strong decrease in TNF- production in response to C10-15 proposing TLR2 as the chitin-
receptor in mammals (Fig.10a). This was supported by the involvement of TLR2 in human 
primary monocyte-derived macrophages (MoMacs), where we knockdown MYD88 and 
TLR2 using siRNAs. Indeed, MYD88 and TLR2 knockdown led to a reduction in IL-6 release 
following stimulation with C10-15. Similar decrease in IL-6 secretion was observed after 
cell treatment with the well-established TLR2 ligands Pam2CSK4 (Pam2) and Pam3CSK4 
(Pam3). Cells treated with TLR2-specific siRNA showed no decrease in IL-6 secretion upon 
stimulation with the TLR4 ligand LPS (Fig.S7).  
 
To confirm this finding and to establish a robust system to test chitin-dependent 
signaling, we co-transfected HEK 293T cells with a human TLR2 construct together with 
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luciferases to assess NF-B activity by a dual-luciferase reporter assay (DLA).  
DLAs demonstrated a TLR2-dependent and dose-dependent response to C10-15 (Fig.10b). 
Of note, in all performed DLAs we stimulated the endogenously expressed TLR5 with 
flagellin (from S. typhimurium) as cell viability and TLR2-independent control.  
 
Next, to test chitin-TLR2 molecular interaction, we pre-treated TLR2 transfected HEK 293T 
cells for DLA with the TLR2-inhibitor SSL3 (staphylococcal superantigen-like protein 3). 
SSL3 is an immune evasion protein, part of a mechanism of defense from Staphylococcus 
aureus, which prevents TLR2 stimulation by pathogen-associated lipopeptides. Koymans, 
et al. presented a crystal structure of SSL3 in complex with TLR2 showing that SSL3 
partially covers the entrance of TLR2 binding pocket and thereby inhibits the binding of 
the TLR2 ligands Pam2 and Pam3 (Koymans et al. 2015). Here, we anticipated that chitin 
would bind to the same TLR2 binding pocket as the lipopeptides (Fig.10d). Hence, SSL3 
would be expected to impair chitin binding and consequent immune response. Indeed, 
SSL3 abolished C10-15-induced NF-B activation and significantly decreased Pam2 and 
Pam3 stimulation (Fig.10e). Likewise, this data was strengthened by other techniques 
illustrated in the manuscript using SSL3 and an anti-TLR2 antibody as blockers of chitin-
TLR2 binding (Fuchs et al. 2018).  Furthermore, the effect of SSL3 on chitin recognition is 
medical relevant since co-infections of S. aureus and pathogenic fungi such as C. albicans 
occur frequently (Morales and Hogan 2010). 
 
Since the Tlr2 KO showed reduced but not total abrogation of a C10-15 response (Figure 
10a), we wanted to check if some of the chitin-receptors suggested by the literature were 
responsible for the remaining cytokine production. The here tested receptors were 
Dectin-1, NOD2 and TLR9, which are the view that have been directly associated to chitin 
(Mora-Montes et al. 2011, Wagener et al. 2014, Marakalala et al. 2013). We used the DLA 
system to evaluate these receptors, in which positive controls were, zymosan for Dectin-
1, MDP (Muramyl dipeptide) for NOD2 and CpG for TLR9. Positive controls showed 
significant differences (p<0.05) compare to unstimulated conditions, but none of the 
receptors were able to induce a chitin-dependent NF-B activation, even using a high 
chitin concentration (5 µM, Fig.10c). Additionally, we evaluated TNF release from WT and 
Dectin-1-deficient immortalized murine macrophages (Clec7a KO iMacs) upon chitin 
stimulation (Rosas et al. 2008) and deficient cells responded as efficiently as WT iMacs (in 
manuscript, Fig.S2d). Thus, we concluded that these tested receptors cannot directly 
mediate chitin-responses, at least in a NF-B manner. 
 
Collectively, we here confirmed TLR2 as a chitin-receptor by triggering the activation of 
NF-B and the subsequent cytokine production. Furthermore, we could abrogate chitin- 
responses by the specific TLR2-antagonist SSL3. At last, we disproved several “chitin-
receptors”, which exclusively were suggested to induce an immune response originated 
by chitin.  
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Figure 10. Chitin 10-15 oligomer induce TLR2-dependent immune response. (a) TNF released 
from WT or MYD88 and TLR2 KO BMDMs upon 18 h stimulation (n=6-9/group measured in 3 
experiments). (b,c,e) DLA measurements of NF-B activation in HEK 293T cells lysates upon transient 
transfection with (b) TLR2 and empty vector; (c) NOD2, Dectin-1 and TLR9. (e) HEK 293T cells 
transfected with TLR2, were treated for 30 min with SSL3 alone, then stimuli were added and 
incubated for further 18 h before lysis. SSL3 was boiled for 10 min at 95°C. (d) Docking of chitin 10 
(magenta) into TLR2 (orange) binding pocket (close-up, pdb 2z7x) and overlaid with SSL3 (red) from 
SSL3-inhibited TLR2 complex (pdb 5d3i). (b,c,e) Shown mean+SD of one representative of n=2-3 
independent experiments. *p<0.05 according to Student’s t-test in all graphs. Note: (a) done by K. 
Fuchs, (c) done with T. Sanmuganantham and (d) by A. Weber. All from the Department of 
Immunology, University of Tübingen. RLU: relative luminescence units; EV: empty vector;  
ECD: ectodomain. 
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3.3.3 Chitin-TLR2 molecular recognition  
 
Having observed that SSL3 was a potent antagonist of receptor activation, binding of 
chitin to the TLR2 hydrophobic pocket was investigated further. We generated TLR2 
constructs with single point-mutations in residues placed at the ligand-binding domain to 
test their potential to induce NF-B activity by DLA upon engagement to Pam2, Pam3 and 
C10-15. The position of the ligand-binding domain was determined by the TLR2/TLR1 
heterodimer crystal structure comprising AA residues from position 266 to 355 (Jin et al. 
2007). Residues L328, V348 and F349 are positioned in the hydrophobic core and dimer 
interface with TLR1. F349 is involved in mediating hydrophobic interactions with TLR1 and 
fixes by strong hydrogen bonds the lipopeptide backbone to the heterodimer (Jin et al. 
2007), in this case Pam3. L328 exchange to K (Lysine) has been demonstrated to abolish 
response to TLR2 ligands: Pam3 and MALP-2 (Kajava and Vasselon 2010, Takeuchi et al. 
2001). V248 mutation could influence the hydrophobic interactions of F349. Thus, 
mutations of these residues were expected to impair chitin-TLR2 signaling by narrowing 
the ligand-binding pocket (Fig.11). Indeed, almost all tested mutations: L328W, V348Y, 
V348W, F349W affected chitin-dependent response, except for V348L. V348L also did not 
block Pam2 and Pam3 responses, presumably because both, valine and leucine, have a 
non-polar and small structure (Fig.11d). V348 exchange to Y and W abrogated all TLR2-
ligands responses (Fig.11f). Interestingly, F349W did not reduce Pam2-induced NF-B 
activity (Fig.11e). This shows a specific involvement of a TLR2/TLR1 mediated response. 
 
Together this data proved TLR2 to be an essential immune sensor for fungal-chitin and 
triggers the consequent activation of NF-B. It also suggests that chitin fits similarly to 
Pam3 in the TLR2 hydrophobic pocket. 
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Figure 11. TLR2 mutations in the hydrophobic binding pocket. (a) TLR2 WT and mutant’s protein 
expression assess by immunoblot with an anti-Flag antibody. (b-f) DLA measurement of NF-B activation in 
HEK 293T cells lysates upon transient transfection with TLR2 constructs having the stated mutations. 
Panels are representatives of n=3 showing means+SD of triplicates. Dash lines represent levels stated by 
TLR2 WT. Mutated constructs were generated by A. Weber and M-T. Dang from University of Tübingen. 
(c-f) Blue dotted line delineates the hydrophobic pocket, shown in cross-section. Black mesh demonstrates 
original surface profile in pdb 2z7x and red mesh the predicted surface of the respective point mutant. 
Dockings were made in Pymol 1.4.1 by A. Weber (University of Tübingen). RLU: relative luminescence 
units.  
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3.3.4 Chitin as TLR2-ligand in the fungal cell wall preparation, zymosan  
 
Zymosan is an insoluble preparation from the cell wall of Saccharomyces cerevisiae 
(yeast) and/or Candida albicans and has often been used as Dectin-1 and TLR2 stimulus. 
However, upon hot alkali treatment (e.g. boiling in a high concentrated sodium hydroxide 
suspension), it loses its capacity to induce a TLR2 response (Walachowski, Tabouret, and 
Foucras 2016, Dillon et al. 2006). Zymosan main constituents are polysaccharides like  
β-glucan and mannan, and was shown to activate macrophages, monocytes and 
leucocytes (Brown et al. 2002). Moreover, it is often used to induce sterile inflammation 
in vivo (Thomas et al. 2008, Malik et al. 2011) and to mimic dust toxic syndrome by 
inhalation of fungi or yeast inducing inflammation and immune responses in the lungs 
(Sato et al. 2003).  
 
Although chitin is known as a constituent of zymosan (Fig.12a and (Di Carlo and Fiore 
1958), it remained unclear which of zymosan’s constituents is the TLR2 ligand and is 
sensitive to a hot alkali treatment (also referred to as “depletion”). Interestingly, such a 
treatment is also used to deacetylate chitin chains (shown in Fig.12b), converting it to the 
non-immunogenic chitosan (Elieh-Ali-Komi and Hamblin 2016). Hence, we hypothesized 
that the TLR2 ligand in zymosan preparations is chitin. Depleted zymosan (also 
commercially available) would lose its potency to induce TLR2-responses, while keeping 
its Dectin-1-dependent immunogenicity. To prove this, we performed depletion of C10-15 
or zymosan and further tested their immunogenic properties. As expected, depletion 
treatment on chitin and zymosan abolished the NF-B activation in TLR2-transfected HEK 
293T cells (Fig.12d). Likewise, zymosan depletion significantly reduced by two fold the 
TLR2-dependent IL-8 secretion from primary PMNs but increased by two fold the ROS 
(reactive oxygen species) production, possibly due to unmasked Dectin-1 ligand produced 
by the treatment (Fig.12e). ROS production can be mediated by Dectin-1 and TLR2 
together, but TLR2 stimulation alone produces very low amounts (Romero et al. 2016). 
Thus, we used it as a Dectin-1 activation read out.   
 
We confirmed the de-acetylation of chitin by treating depleted C10-15 with a 
recombinant bacterial chitinase (from Streptomyces griseus), in order to get soluble 
dimers. The resulting chitin and chitosan dimers were then quantified by mass 
spectrometry. Spectrums showed that >90% of chitin oligomers were de-acetylated upon 
depletion treatment (Fig.12c). Likewise, chitin contained in zymosan was assessed in a 
similar way (Fig.12a).  
 
This data confirms our hypothesis that the chitin content in zymosan, presumably at 
oligomeric sizes, is the main TLR2-ligand whose immunogenicity can be eliminated by 
depletion treatment. To our knowledge, this is the first study to identify chitin as  
TLR2-ligand present in zymosan. 
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Figure 12. Chitin as TLR2-ligand in zymosan preparation. Mass spectrometry analysis of (a) 
zymosan and (c) C10-15 original and depleted upon treatment with bacterial chitinase to produce 
soluble dimers of the oligomeric chains. (b) Deacetylation reaction by hot alkali treatment and 
deacetylases. (d) NF-kB DLA from TLR2 transfected HEK 293T cells lysates upon 18 h stimulation and 
48 h transfection, representative of n=2. (e) IL-8 and ROS production of primary PMNs upon 4-3 h 
stimulation, n=7. * p<0.05 according to Student’s t-test (d) and Wilcoxon signed rank sum (e). Data 
presented in (e) was generated by F. Herster and (a,c) together with N. Schilling (both from the 
University of Tübingen). RLU: relative luminescence units. 
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3.3.5 TLR2 co-receptor for chitin-response in human HEK cells  
 
TLR2 in complex with TLR1 or TLR6 recognizes triacylated and diacylated lipopetides, 
respectively. However, to this date, the TLR2 co-receptor for chitin recognition has not 
been determined. Ozinsky, et al. demonstrated that TLR2 together with TLR6 mediated 
macrophages activation by zymosan particles placed in phagosomes (Ozinsky et al. 2000). 
Thus, together with our discovery that TLR2 ligand in zymosan is chitin, these findings 
would suggest that chitin is recognized by the TLR2/TLR6 heterodimer. On the other 
hand, we noted that chitin bound to the TLR2 hydrophobic pocket similarly to Pam3, 
since F349W and L328W mutations affected sensing of both ligands (Fig.11). This fact 
would suggest a TLR2/TLR1 dimer as responsible to induce a chitin-dependent response.  
 
Thus, to reveal which co-receptor is responsible to assist TLR2-chitin signaling, we used 
siRNAs to knockdown TLR1 or TLR6 in HEK 293T cells transfected with TLR2 for NF-B di-
luciferase assays. HEK 293T cells constitutively express TLR1 and TLR6, although at low 
levels. Nevertheless, since the single transfection of TLR2 induced NF-B activation upon 
stimulation with Pam2 (TLR2/TLR6-ligand) and Pam3 (TLR2/TLR1-ligand), we took for 
granted that their endogenous levels were enough to mediate TLR2-dependent signaling. 
As negative control we knocked down TLR5, also expressed in HEK cells. Results showed 
that TLR1 and TLR6 knockdown significantly reduced NF-B activity. TLR6 knockdown had 
the strongest effect showing ~70% decrease in NF-B activity (Fig.13a). TLR1 knockdown 
showed ~55% reduction of NF-B activity. This data suggested that both heterodimers 
might be equally important for chitin recognition, since endogenous expression of TLR1 
and TLR6, and siRNA efficiencies could influence the reduction differences but not the 
signal blockage.  
 
For further validation we used a TLR6 dominant negative (DN, p.P680H) construct to 
support TLR6 as a co-receptor candidate. This mutation of proline to histidine in the TIR 
domain confers a dominant negative function of any TLR and was first described for TLR4 
(Haase et al. 2003). Using again the HEK 293T cells transfected with TLR2 for DLA, we here 
co-transfected TLR6 DN in overexpression amounts to theoretically form heterodimers 
with all available TLR2. The presence of TLR6 DN decreased chitin-dependent NF-B 
activity by half, but the positive control Pam2 was only reduced 30%, and no plasmid 
dose-dependent effect was observed (Fig.13b). This data could support redundancy 
between TLR1 and TLR6. To support this idea we could test next a TLR1 DN construct in 
the same system.  
 
At last, using the same system, we tested the receptor TLR10 as potential co-receptor for 
sensing of chitin. Two constructs of TLR10 were tested (here only one is shown, since 
results were the same) but none enhanced the C10-15-induced NF-B activity in TLR2 
transfected cells. Furthermore, in contradiction with the literature (Oosting et al. 2014) 
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neither TLR10 construct reduced Pam2 or Pam3 responses (Fig.13c). Thus, in our system 
TLR10 neither supported nor inhibited chitin-TLR2 response.  
 
 
 
 
 
 
 
 
 
 
   
Figure 13. TLR1, TLR6 and TLR10 as potential TLR-2 co-receptor for chitin. NF-B activity 
upon 18 h stimulation of HEK 293 T cells transfected with the corresponding luciferases plus (a) TLR2 
and siRNAs against TLR1 TLR6 and TLR6, or (b) TLR2 and TLR6 DN, or (c) TLR2 or TLR10 alone or 
together. Graphs are representatives of (a) n=4, (b) n=3 and (c) n=3 and error bars are mean+SD 
from triplicates. *** p<0.001 according to Student’s t-test. DN: dominant negative; RLU: relative 
luminescence units. 
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3.3.6 TLR2 co-receptor for chitin-response in murine BMDMs 
 
To extend the search for the TLR2 co-receptor to the murine system, we used BMDMs 
(bone marrow derived macrophages) from Tlr2, Tlr1 and Tlr6 KO and wildtype mice. We 
stimulated differentiated macrophages for 18 h with C10-15 and used Pam2 and FSL-1 as 
TLR2/TLR6 controls, Pam3 as TLR2/TLR1 control and LPS as TLR2-independent stimulus. 
Then, as activation readout we measured secreted IL-6 amounts by ELISA. This showed no 
differences among KO and WT murine cells in unstimulated and LPS conditions. As 
expected, Tlr2 and Tlr1 KO BMDMs showed significantly lower IL-6 production upon Pam3 
stimulation (p≤0.03); likewise, Tlr2 and Tlr6 KO secreted significantly lower cytokine upon 
Pam2 (p≤0.05) and FSL-1 (p≤0.01) stimulation in comparison to WT cells. Thus, all controls 
worked well. Although Tlr1 and Tlr6 KO BMDMs showed a trend towards a reduced 
response to chitin when compared to WT cells, the difference failed to be significant; only 
Tlr2 KO showed a two-fold lower IL-6 levels than WT BMDMs (p≤0.04) (Fig.14).  
 
Collectively these data proposed that chitin could use either co-receptor TLR1 or TRL6 to 
induce an immunogenic response, perhaps preferring TLR1 since C10-15 showed more 
similarities to Pam3 stimulus using the TLR2 mutants. Nevertheless, we do not discard the 
possibility of a still unknown TLR2 co-receptor.  
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Figure 14. Assessing TLR2 co-receptor for chitin sensing in the murine system. Murine IL-6 
production upon 18 h stimulation of BMDMs with the stated ligands measured by ELISA. BMDMs were 
differentiated with murine GM-CSF for 6 days. WT mice n=3 and others n=4. Chitin stimulus was tested 
in a 1:5 dilution, other stimulus at 1:20 dilution and unstimulated without dilution. P values stated are 
according to Student’s t-test. All mice were tested in one experiment performed together with  
Z. Bittner and F. Herster from University of Tübingen. 
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3.4. Discussion  
 
Different receptors have been proposed to mediate the sensing of chitin leading to an 
immune response. However, direct binding of chitin to the suggested receptors and 
corresponding molecular studies remained elusive. One technical limitation faced by 
previous studies has been the lack of defined and pure chitin. In our study, using pure 
chitin oligomers, we identified chitin as a TLR2 ligand.   
 
The use of oligomeric chitin matched the dimensions of PRRs ectodomains and allowed us 
to show trustable molecular studies covering the chitin-TLR2 interaction. Previously, we 
found six NAGs to be the minimum size for induction of an immune response in mammals 
and this was largely increased by a mixture of 10-15 NAGs, which we used in the following 
experiments. Although C10-15 showed the highest immunogenicity, it is worth to discuss 
that we used this mixture because it is extremely difficult to 1) synthesize specific size 
oligomers bigger than 6 subunits, particularly in milligram scales and 2) separate them by 
sizes upon isolation from raw material. These limitations are attributed to the insoluble 
nature of chitin (Younes and Rinaudo 2015). Despite the broad occurrence of chitin in 
nature, the main commercial sources are crab and shrimp shells. Its industrial process by 
extraction from crustaceans involves many laborious steps and solubility remains a big 
issue (reviewed in (Younes and Rinaudo 2015)). Therefore, the most demanded chitin 
source is chitosan a chitin derivative used in biomedical products. Chitosan is more 
soluble than chitin and is generated by chitin deacetylation under alkaline conditions. 
Notably, its purity is of high importance since it is commonly utilized for biomedical 
products, in which residual proteins or pigments could cause many side effects. One 
example is a chitosan bandage used for the control of hemorrhage and wound healing 
(Burkatovskaya et al. 2008, MacIntyre, Quick, and Barnes 2011). Then, the raw source of 
our chitin preparation is chitosan oligomers varying from 10 to 15 subunit sizes, which 
were acetylated according to well established protocols (Bueter et al. 2011) and treated 
to be endotoxin free. Together, all these arguments support the quality and purity from 
the here used oligomeric chitin lacking other potential components that could cause an 
immune response. Interestingly, such chitin oligomers were used before to discover the 
chitin-receptor in plants (Kaku et al. 2006). Moreover, we and others (Kuusk, Sorlie, and 
Valjamae 2017) propose that chitinases, specially endochitinases, could degrade 
pathogen-derived chitin-containing structures and once released, oligosaccharides  (e.g. 
C6-15) could subsequently trigger an immune response. Together, the oligomeric chitin 
used in this study is a good tool to approach the aimed molecular studies.  
 
C10-15 allowed us to define TLR2 as a decisive receptor for chitin and the major player in 
the subsequent inflammatory response in human and murine immune cells. However, 
murine Tlr2 KO BMDMs did not show complete abrogation of chitin responses raising the 
possibility that another receptor might be involved. Dectin-1 (Da Silva et al. 2009), TLR9 
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and NOD2 (Wagener et al. 2014) were candidates suggested by others, which we also 
tested here. But, they failed to induce the activation of NF-B upon chitin stimulation in 
HEK 293T cells and Dectin-1 KO iMacs; therefore, we discarded them as potential 
mediators of the residual immune signal in Tlr2 KO cells. Nevertheless, we cannot rule out 
the possibility that they could regulate chitin-signaling as it was proposed for Dectin-1. 
For example, it was demonstrated that chitin blocks Dectin-1 binding and response to  
ß-glucans from Candida albicans cell wall (Mora-Montes et al. 2011); and that differences 
in the levels of cell-wall chitin influence the capacity of Dectin-1 to control C. albicans 
infection (Marakalala et al. 2013). Furthermore, there are several publications suggesting 
that Dectin-1 and TLR2 synergize inflammatory responses, e.g. TNF or ROS secretion, 
triggered by each receptor (Goodridge and Underhill 2008, Ferwerda et al. 2008). Other 
probable receptors, not tested here, might be Mincle, DC-SIGN (SIGNR1 homolog) and the 
mannose receptor, all CLRs, which also recognize sugars and have been shown to be 
involved in fungal recognition (Mora-Montes et al. 2011, Takahara et al. 2012, Wells et al. 
2008), nevertheless their association to chitin remains to be assess. For example, Mincle 
KO macrophages were already used to show Mincle sensing of C. albicans by Well, et al. 
(Wells et al. 2008) and the mannose receptor (MR) KO has been generated (Lee et al. 
2002) and tested again in response to C. albicans (van de Veerdonk et al. 2009). Thus, 
chitin-response experiments could be done by stimulating the corresponding KO innate 
immune cells with the here used C10-15 to rule out or associate these receptors directly 
to chitin. 
 
More importantly, we proved here the direct binding of chitin to TLR2. Using direct 
mutagenesis, we could modify the TLR2-binding pocket and block TLR2-ligand responses 
including chitin. Furthermore, we confirmed this result by utilizing the TLR2-antagonist 
SSL3. The direct binding was also supported by microscale thermophoresis analysis 
measuring the binding of chitin to recombinant TLR2 and by TLR2 staining in  
C. albicans cells measured by flow cytometry analysis (in manuscript). Collectively, we are 
the first to show chitin-TLR2 direct sensing and binding at the molecular level. Of interest, 
the inhibition of chitin recognition by SSL3 warrants further analysis in S. aureus/C. 
albicans co-infections (Morales and Hogan 2010), since it could attenuate host response 
against concomitant fungal infection in a chitin-TLR2-dependent manner. 
 
At last, we aimed to find the TLR2 co-receptor responsible to mediate the chitin-induced 
TLR2 activation. Our knockdown and knockout experiments of the main TLR2 co-
receptors, i.e. TLR1 and TLR6, did not show an exclusive preference. Although one study 
showed that TLR2-response to zymosan requires TLR6 (Ozinsky et al. 2000), we speculate 
that TLR2 might use both co-receptors for the sensing of chitin. Potentially, chitin-TLR2 
complex might be more stable with TLR1 since TLR2 mutants in the binding pocket 
impaired Pam3 and C10-15 similarly. Nevertheless, the idea of another still unknown TLR2 
co-receptor is imaginable. Preliminary data showed that double KO of TLR1 and TLR6 in 
 56 
HEK cells, which stably express TLR2, were unable to induce NF-B activation when 
stimulated with C10-15. But single KO reduced chitin-responses by 50% compared to TLR2 
HEK cells (not shown). We also do not exclude that immune cells might express co-
receptors that are absent in HEK cells. Therefore, we suggest that TLR1 and TLR6 remain 
the main candidates and warrant further research. Of immediate importance would be to 
test in our DLA system a TLR1 dominant negative construct, expecting a chitin-response 
reduction of 50% as observed for TLR6 DN to confirm redundancy and performed double 
knockdown or/and knockout of TLR1 and TLR6 in e.g. macrophages to rule out the 
existence of another co-receptor. 
 
Overall, our study resolved the missing link between 1) fungal immunogenicity and the 
previously observed TLR2 response in murine infection models (Cunha, Romani, and 
Carvalho 2010, Goodridge and Underhill 2008) and 2) house dust mite allergic symptoms 
mediated by TLR2 (Ryu et al. 2013). Thus, this project raises the possibility to use chitin 
oligomers as tools for further research about fungal infections and chitin-related allergies, 
which now could concentrate on chitin-TLR2 binding and activation. Moreover, the 
confirmed chitin-TLR2 interaction can become an attractive target for the development of 
molecules against the TLR2 hydrophobic core to treat chitin-related pathologies, since our 
study demonstrated a chitin-response reduction with SSL3-peptides and TLR2 blocking 
antibody treatments.  
  
 
3.5 Conclusion 
 
Chitin preparations used in previous studies, in which different chitin-receptors had been 
proposed, were large chitin particles and with variable purities. Thus, findings remain to 
be confirmed and assess by different approaches. Here, we used defined and pure chitin 
oligomers to confirm the chitin recognition by the Toll-like receptor 2 and disproved other 
previously suggested candidates. Furthermore, we are the first to provide conclusive 
molecular evidence for a direct TLR2-chitin interaction and to identify chitin as TLR2-
ligand present in zymosan. Finally, we demonstrated that the chitin-TLR2 complex could 
use both TLR1 and TLR6 as co-receptor. Hence, inflammation and allergic symptoms in 
fungal infection and asthma could now be attributed to the recognition of chitin by TLR2 
in immune cells and the resulting potent inflammatory response. Thus, our study 
highlights chitin oligomers as a valuable tool to study fungi-host interactions and the 
TLR2-chitin interaction as an attractive target for the development of novel therapies in 
chitin-related pathologies and fungal diseases. 
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Chapter 4: Materials and Methods  
4.1 General Methods  
 
4.1.1 Cell maintenance  
 
Cell culture media used here were Dulbecco´s modified Eagle’s medium (DMEM) and 
RPMI-1640 from Sigma Aldrich, and alpha-MEM from Gibco. For supplements heat-
inactivated fetal calf serum (FCS) from Biowest; penicillin, streptomycin, L-glutamine from 
Gibco were used. For harvesting, Dulbecco´s Phosphate Buffered Saline (DPBS) and 
Trypsin from Gibco were utilized. Human serum was obtained from fresh blood from the 
same donor whose B cells were isolated. All cell lines were maintained at 37 °C and 5% 
CO2 in a humidified incubator. Maintenance media are summarized in the table below.   
 
 
Table 4. Maintenance medium used during experiments 
Cell type  Medium  Supplements  
HEK 293 T WT and 
MyD88-deficient (I3A) 
DMEM 
10% (vol/vol) heat-inactivated FCS,            
100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
DLBCL cell lines      
BJAB, TMD8, HBL-1 and     
Oci-Ly3 
RPMI-1640  
20% (vol/vol) heat-inactivated FCS, 
100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
Oci-Ly19 alpha-MEM 
10% (vol/vol) heat-inactivated FCS, 
100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
Human primary cells      
PBMCs, Monocyte-
derived macrophages 
and Neutrophils 
RPMI-1640  
10% (vol/vol) heat-inactivated FCS, 
100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
B cells  RPMI-1640  
10% (vol/vol) human serum, 100 
U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
Murine cells      
Bone-marrow derived 
macrophages  
RPMI-1640  
10% (vol/vol) heat-inactivated FCS, 
100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine  
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4.1.2 Human primary cells isolation and analysis 
 
PBMCs 
Human peripheral blood mononuclear cells (PBMCs) were purified from whole blood or 
buffy coats (University Hospital Tübingen Transfusion Medicine) using Biocoll density 
gradient (Millipore) and subsequently washed twice with DPBS. PBMCs were resuspended 
and maintained for experiments in supplemented RPMI and rested at least 4 h prior to 
stimulation. 5x10^6 cells were stimulated with the stated ligands and concentration for 0, 
6, 12 and 18 h, then cells were lysed in RLT buffer + -mercaptoethanol (Qiagen) for  
RT-qPCR experiments described below.  
B cells  
Primary B cells were isolated from PBMCs by negative selection using B Cell Isolation Kit II 
(Miltenyi Biotec), according to instructions with the following modifications:  
I resuspended cells in 17 µl Buffer, used 8 µl of Biotin-Antibody Cocktail (10 min), 15 µl of 
Anti-Biotin MicroBeads (15 min) per 10^7 PBMCs. B cell isolation always reached >90% 
purity and cells were seeded in supplemented RPMI with human serum and rested for at 
least 4 h before the experiment. 5x10^6 cells were stimulated for 0, 2, 3, 4, 5 days with 
2,5 µg/ml CpG 2006 and 5 μg/mL IgM and processed for RT-qPCR, or 1x10^6 cells were 
stained on day 0 with carboxyfluorescein-succinimidyl ester (CFSE, Life Technologies) to 
track cell proliferation. Purity of the isolated cells was assessed by flow cytometry on a BD 
FACSCanto™ II system staining cells with anti-CD19 Pacific Blue, anti-CD3 FITC, anti-CD14 
PE und anti-CD11b APC (Biolegend). Graphs were done with software FlowJo PC  
version 10.  
Human monocyte-derived macrophages (MoMacs) 
Human macrophages were generated by purifying monocytes out of PBMCs using anti-
CD14 microbeads (Miltenyi Biotec, >90% purity). Monocytes were differentiated in 
complete RPMI supplemented with human recombinant GM-CSF (Prepro Tech) for 6 days 
as described (Verreck et al., 2004). On day 5, cells were collected and plated in 96 well 
plate-format (100,000 cells/well). For knockdown experiments, MoMacs were transfected 
with 35 nM of corresponding siRNA (Table 7, GE Dharmacon) using Viromer Blue (Biozol). 
On day 6 cells were stimulated for 18 h with C10-15, LPS, Pam2 and Pam3. Supernatants 
were collected and analyzed for human IL-6 levels by ELISA.  
Neutrophils  
Fresh whole blood from healthy donors collected in EDTA tubes was processed to isolate 
neutrophils. Briefly, whole blood cells were separated depending on their density using 
Biocoll (Millipore); the resulting pellet below the Biocoll phase contains mainly 
neutrophils. The neutrophil-erythrocyte pellet was treated twice with 1x Ammonium 
chloride buffer for erythrocyte-lysis (10X Stock: 1.54 M NH4Cl, 100 mM KHCO3 and 1 mM 
EDTA adjusted to pH 7.3); the first treatment was for 20 min and second for 10 min at 
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4°C. Cells were resuspended in complete RPMI, seeded immediately in 24-well plates for 
experiments and rested for 1 h. Cells more than 95% pure and not pre-activated were 
used. For ROS assays, 2x10^5 neutrophils in 100 µl were mixed with 100 µl DCF (2’,7’-
dichlorofluorescein; final concentration 10 µM) plus ligands and DCF fluorescence was 
measured every 5 min for 3 hours using the Fluorstar Optima plate reader at 37°C (BMG 
Labtech). Only the last fluorescence value was used for the graphs. For human IL-8 ELISA, 
1x10^6 cells were plated and stimulated for 4 h and supernatants were collected. 
 
4.1.3 Immunoblotting 
 
Expression of endogenous proteins and proteins derived from plasmids was checked by 
Western Blot. For this, whole cell lysates (WCL) were obtained by washing cells once with 
PBS and resuspending cells with either passive lysis buffer from Promega or with RIPA 
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% SDS, 1% 
Triton X-100 and 0.5% deoxycholate) supplemented with PhosSTOP, EDTA-free protease 
inhibitor cocktail (both from Roche) and 0.1 μM PMSF. WCL were mixed with reducing 
agent and loading buffer (Novex, Thermo Fisher) and boiled 5 min at 95°C for 
denaturation. Samples were run on 10% or 12% Tris-glycine gels with SDS buffer (25 mM 
Tris-base, 250 mM glycine and 0.1% SDS), loading corresponding volumes to ~20 µg 
protein onto the gel. Separated proteins were transferred onto nitrocelullose membranes 
(GE Healthcare, 0.2 µm) and blocked at room temperature in 10 ml of 5% BSA (wt/vol) in 
Tris-buffered saline solution with 0.1% (vol/vol) Tween-20 (TBS-T). Subsequently, 
nitrocellulose membranes were incubated with 5 ml diluted specific primary antibodies in 
5% BSA in TBS-T overnight at 4°C with rotation. On the next day, membranes were 
washed 3 times with TBS-T for 5 min each and then incubated with the corresponding 
secondary antibodies diluted in 8 ml 5% BSA in TBS-T for 1 h at RT with rotation. After 
incubation with the secondary antibodies, membranes were washed 3 times with TBS-T, 5 
min each wash. Detection was done by chemiluminescence (Peqlab) and development 
using a CCD (charge-coupled device) camera to capture the luminescent signals. Pictures 
were analyzed and edited in Phusion (Peqlab) and Adobe Illustrator programs. 
Information regarding all the antibodies used, including dilutions, can be found in Table 5. 
 
4.1.4 Dual NF-B Luciferase assay in HEK 293T cells   
 
75,000 HEK 293T (WT or MyD88-deficient I3A) cells were plated (24-well format, Greiner 
Bio One) and incubated overnight to allow adherence. On the next day, cells were 
transiently transfected with the following amounts of plasmid DNA per well: 100 ng EGFP 
as a transfection control, 100 ng of firefly luciferase under the NF-B promoter and 10 ng 
of Renilla luciferase under a constitutive promoter. Additionally, varying amounts of 
plasmid encoding the gene of interest were added. For the tested chitin-receptors 10-25 
ng were used. For MyD88 isoforms 1-100 ng were used. Each set of transfections was 
 60 
adjusted with empty vector to equal amount of total variable plasmid (100 ng) and was 
accompanied by negative controls containing the corresponding empty vector at the 
same total amount of variable plasmid (for a list of plasmids, see Table 8). Transfection 
was performed using Lipofectamine 2000 (Thermo Fisher) with a total volume of 50 µl per 
well as supplier instructions. Transfections and pre-dilutions were prepared using 
OptiMEM. If stimulation was required, after 32 h incubation, the medium was discarded 
and exchanged with fresh complete DMEM with or without the ligands to be tested. Cells 
were stimulated for 18 h and measurements were carried out immediately. Supplier 
information and the concentrations of all ligands are summarized in Table 6. For MyD88 
splice variant analysis, measurements were performed 48 h post transfection. To analyze 
luciferase activity, cells were washed in PBS and subsequently lysed in passive lysis buffer 
(Promega). Lysates were harvested by centrifugation and 10 µl of lysate was used to 
measure luciferase activity on a FluoStar luminescence plate-reader (BMG Labtech), 
which automatically added the corresponding substrates, Luciferase Assay Reagent II for 
the firefly luciferase and Stop & Glo Reagent to quench the firefly luciferase and initiate 
reaction for Renilla luciferase, both reagents from Promega. Analysis settings were 
chosen as recommended in the Dual-Luciferase Reporter Assay System by Promega. 
Graphs and statistics were done in GraphPad Prism version 6.  
 
 
4.2 MyD88 alternative splicing Methods 
 
4.2.1 MyD88-isoforms plasmids 
 
To study the expression of all MyD88 isoforms and their ability to induce NF-B 
activation, expression constructs were generated in pTO-N-SH vector using the Gateway 
cloning system (Thermo Fisher). The coding sequences (CDS) of MyD88 isoforms 3, 4 and 
5 (NCBI accession numbers NM_001172568.1, NM_001172569.1 and NM_001172566.1, 
respectively) were synthesized by the company Genewiz and cloned into a pDONR207 
vector. MyD88 isoform 1 (NM_001172567.1) was purchased from Harvard Plasmids 
(HsCD00296025) in a pDONR221 vector. To clone the CDS in the pTO-N-SH destination 
vector, an LR-reaction was performed according to kit instructions (Gateway® LR 
Clonase® II Enzyme mix, Thermo Fisher). pTO-N-SH vector, a destination vector from the 
Gateway system, adds a fused StrepIII-Hemagglutinin tag at the N-terminus of the gene of 
interest (vector map Fig.S1a). The final destination vectors were transformed in the DH5 
alpha E.coli strain and to prove the correct insertion of the CDS a BsgI (New England 
Biolabs) digestion was made from at least 3 resulted colonies (300 ng plasmid and 5 units 
enzyme in 1X Buffer Tango, 1 h at 37°C). The colonies that showed the right digestion 
pattern in 1% Agarose gel were tested for protein expression by immunoblotting and 
used for further experiments. For plasmids’ detailed origin information see Table 8. 
Expression plasmid map example in Figure S1.  
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The corresponding L265P mutation and corresponding insertion, depending on the 
isoform, were introduced to the CDS of the MyD88 isoforms using the QuikChange II XL 
site-directed mutagenesis kit (Agilent) according to the manufacturer’s instructions using 
the primers listed in Table 9. Mutagenesis primers were designed in Geneious software 
5.5.9 following the requirements stated in the kit. The introduction of the exact desired 
mutation to the isoforms was confirmed by Sanger sequencing (GATC Biotech). 
 
4.2.2 B cell immunohistochemistry 
 
The protocol for proliferation staining of human B cells was kindly provided by F. Lelis 
from D. Hartl’s group at the University Hospital of Tübingen. A stock solution of 1 mM 
CFSE was diluted in 5625 µl PBS, then 1 ml B cells (resuspended in PBS, 2.5x10^6/ml) with 
1.5 ml CFSE dilution were mixed and incubated 12 min at 37°C. To remove any free dye,  
4 ml FCS + 8.5 ml RPMI medium were added. The tube was centrifuged at 350 x g for 5 
min to pellet the cells, which were then resuspended at 1x10^6/ml in the corresponding 
medium for primary B cells (see Table 4). B cells were stained with CFSE immediately 
upon isolation and stimulated for 5 days with 2.5 µg/ml CpG 2006 and 5 μg/mL IgM.  
On day 5, B cells were washed by centrifugation with PBS and stained with anti-CD19 
Pacific Blue (Biolegend, diluted 1:1000 in PBS). After staining, cells were washed again 
with PBS and analyzed on a BD FACSCanto™ II system with 488 nm excitation for CFSE and 
405 nm for Pacific Blue. Graphs were generated using FlowJo PC version 10.  
 
4.2.3 Primers and qPCR analysis  
 
5x10^6 cells per condition were seeded at the beginning of the experiments. Following 
treatment, cells were washed once with DPBS and lysed in 350 µl RLT buffer +  
-mercaptoethanol at -80 °C. Total RNA isolation was performed by a Qiacube robot using 
reagents from the RNeasy Mini Kit from Qiagen including DNA digestion (RNase-Free 
DNase Set, Qiagen). mRNA transcription to cDNA was done manually using High Capacity 
RNA-to-cDNA Kit from Thermo Fisher. Quantitative PCR was performed in 10 µl total 
volume containing 20 ng cDNA, 0.3 µM of forward primer and 0.3 µM of reverse primer, 
1x SYBR Green (FastStart Universal SYBR Green Master Rox, Sigma) and RNA-free water. 
Each sample was analyzed in triplicates in a real-time cycler (Thermo QuantStudio 7 Flex, 
Thermo Fisher). The cycling profile applied was: 10 min/95 °C; 40 cycles of 95 °C/15 s and 
60 °C/1 min, followed by a continuous melt curve stage from 50°C to 95°C. 
 
Primers generated to discriminate the MyD88 isoforms were situated at the exon 
junctions and fulfill compatibility requirements with the SYBR Green mix, which were 
evaluated in the program Geneious Pro version 5.5.9 and the publicly available software 
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/). Primer sequences and more details are 
found in Table 10. Standard curves were done using the same cycling profile as explained 
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above utilizing plasmids as templates, which were diluted 1 to 5 six times. Results were 
analyzed with the QuantStudio 6 and 7 Flex software and graphs and statistics were 
generated using GraphPad Prism version 6.  
 
4.2.4 RNAseq data analysis  
 
RNAseq libraries from 190 B cell lymphoma samples, including Burkitt’s Lymphoma (BL, 
n=21), Follicular Lymphoma (FL, n=83), Diffuse Large B cell Lymphoma (DLBCL, n=72), and 
FL-DLBCL (n=14) were acquired by the German ICGC MMMLSeq consortium and were 
uploaded as part of several publications to the European genome-phenom archive at EBI: 
https://www.ebi.ac.uk/ega/home. Naïve B cells (B cells, n=5) and germinal center B cells 
(GC B cells, n=5) libraries were used as control data and were made public in the same 
way. Details for library preparation can be found under the access ID listed in Table S3 
and related papers: Hübschmann, D. et al.; Lopez, C. et al. both unpublished and others 
cited (Hezaveh et al. 2016, Kretzmer et al. 2015, Richter et al. 2012). To visualize 
alternative splicing events, RNA sequencing data was mapped onto the human hg38 
reference genome using Segemehl version 2.0 alpha. Segemehl is a tool that maps 
splicing sites into the gene of interest and provides a list of all spliced reads as an output 
(Hoffmann et al. 2014). Splice reads overlapping with the human MYD88 gene were 
counted and visualized in Sashimi Plots based on UCSC genome browser tracks.  
The Sashimi Plots show genomic reads converted into density reads (y-axis, units) aligned 
to the genomic coordinates (x-axis), where arcs represent read junction. Their width is 
proportional to the number of reads aligned to the junctions of the splice sites (Yarden 
Katz, 2015).  A compositional data approach used in the DIEGO software (Doose et al. 
2018) was applied to analyze differential splicing patterns of the MYD88 gene: the 
support number of every splice junction is considered relative to all splice junctions of the 
MYD88 gene, and possible variations are analyzed using Wilcoxon’s rank sum test as 
implemented in R. Boxplot graphics were generated using R’s ggplot2.  
 
A novel splice site within exon 3 (20 nucleotides upstream of a canonical donor) found in 
segemehl mapping showed a Human Splicing Finder (HSF) score of 81. Typically, a score 
above 65 is considered a strong splice site (Desmet et al. 2009). This was confirmed using 
BLAT (UCSD). For intron retention analysis, we applied the number of spliced 
reads/number of total reads on MYD88 as a proxy. 
 
RNAseq analysis was performed by SH. Bernhart at the Interdisciplinary Centre for 
Bioinformatics, University of Leipzig, and coordinated by R. Siebert from the Institute of 
Human Genetics, University Hospital of Ulm.  
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4.3 Chitin-TLR2 interaction Methods 
 
4.3.1 Receptors plasmids 
 
Many of the plasmids expressing PPRs used in this study were kind gifts from different 
research laboratories and are summarized in Table 8 and Table S2. Mutations in the 
hydrophobic binding pocket of TLR2 were introduced using the QuikChange II XL site-
directed mutagenesis kit (Agilent) following the manufacturer’s instructions. Primer 
design was done by A. Weber (see Table 9) and mutagenesis by T-M. Dang (both from 
Department of Immunology, University of Tübingen). Correct introduction of the desired 
mutations was confirmed by automated Sanger sequencing (GATC Biotech). 
 
4.3.2 siRNAs mediated knock-down of TLRs in HEK 293T 
 
HEK 293T cells were transfected with plasmids used for NF-B DLA, using as a variable 
plasmid TLR2 (10 ng/well) described in Section 4.1.4. siRNA pools to knock-down TLR1, 
TLR6 and TLR5 were transfected together with the plasmids using Lipofectamine 2000. 
Supplier and catalog IDs are listed in Table 7. Final concentration of siRNA per well from a 
24 well-plate was 20 nM.  After one day of transfection cells were stimulated with the 
corresponding ligands for 18 h and lysates were prepared to measure NF-B activity by 
luminescence. Knock-down efficiency was evaluated by qPCR showing a stable reduction 
of ~70% of the targeted mRNA molecules after 24 and 48 h of transfection (not shown, 
tested by T. Sanmuganantham and S. Dickhöfer). 
 
4.3.3 ELISA (enzyme-linked immunosorbent assay)  
 
Cytokines in supernatants were measured by ELISA as per the manufacturer's instructions 
using triplicate points. Human IL-6 and IL-8, murine IL-6 and TNF ELISA kits were from 
BioLegend. Briefly, coating antibody was applied to high binding 96 well plates (half area, 
from Greiner Bio-One) and incubated overnight at 4°C. On the next day, plates were 
washed three times with PBS. Plates were blocked with BSA for 1 h at RT and 
subsequently washed with PBS; then supernatants were added using the corresponding 
dilutions listed below. Sample supernatants were incubated at RT for 2 h. A third washing 
step was applied, biotinylated detection antibody was added and incubated for 1 h 
followed by three washes and the addition of Avidin-HRP for 30 min. A final washing step 
was done, the substrate solutions were added and incubated for 5-20 min. Finally, the 
stop solution (sulfuric acid) was added and absorbance was measured on a standard plate 
reader. Antibody and reagent concentrations were applied as recommended.  
 
For murine IL-6 and TNF ELISA, BMDMs supernatants were diluted as followed: for LPS, 
Pam2, Pam3 and FSL-1 stimulations 1:20; for C10-15 1:5 and unstimulated conditions 
were not diluted. Supernatants from TLR2 KO BMDMs were also not diluted when 
 64 
stimulated with TLR2-ligands. For human IL-8 ELISA 1:3 dilutions of the supernatants were 
appropriate.   
 
4.3.4 Chitin preparation 
 
Chitin 10-15 subunits length, referred in the figures as C10-15, was produced by 
acetylating chitosan oligomers from the same length as previous described (Bueter et al. 
2011). In detail, >95% pure chitosan with a molecular weight of 2000-3000 g/mol, 
equivalent to 10-15 subunits (from Pure Science), was resuspended in freshly prepared  
1 M sodium bicarbonate, then 97% acetic anhydride was added, and the preparation was 
incubated at RT for 20 min, followed by incubation at 100° C for 10 min. The resulting 
chitin was washed with DPBS until pH was neutralized and then washed with water to 
remove salt content. C10-15 acetylation degree was assessed by ESI and analysis was 
kindly done by C. Täumer (Protein Center Tübingen, University of Tübingen). A degree of 
acetylation of >90% was achieved.   
 
For cell culture experiments, the generated C10-15 was treated with Polymyxin B 
(Thermo Fisher) to remove endotoxin. At least 3 washes with Polymyxin B at a 
concentration of 2 mg/ml were done for 3 h each. Endotoxin levels were tested using the 
limulus amoebocyte lysate (LAL) assay (Lonza, CH) achieving endotoxin levels below 0.25 
EU/ml (25 pg/ml LPS) in final dilutions. 
 
4.3.5 Chitin and zymosan depletion  
 
C10-15 and zymosan depletion was performed by hot-alkali treatment, treatment that 
causes de-acetylation converting chitin in chitosan. In detail, C10-15 (1 mM) and zymosan 
(10 mg/ml) dissolved in water were the starting material. First, 500 µg (50 µl) of zymosan 
or ~600 µg (200 µl) C10-15 were pelleted by centrifugation at maximum speed and the 
supernatant was removed. The insoluble fraction was resuspended in 2 ml 10 M NaOH 
and boiled at 95°C for 1 h. After cooling down the reaction at RT, the suspensions were 
washed 3 times (or more) with sterile DPBS to obtain a neutral pH and then washed twice 
with sterile water to remove salt contains. The reagents were resuspended in endotoxin-
free water (Braun) at the starting concentrations for further experiments.  
 
To check the deacetylation of C10-15 and chitin content in zymosan upon depletion, we 
treated depleted reagents with a chitinase from Streptomyces griseus (Sigma), an exo-
chitinase that cuts out N-acetylglucosamine dimers (di-NAG). For this, we mixed 30 µl 
C10-15 1 mM or 100 µg zymosan in water, added volatile pyridine/glacial acetic acid 
buffer (pH 6.5) to a final concentration of 20 mM and 0.25 units Chitinase per 50 µl 
reaction and incubated for 18 h at 37°C. Then, preparations were centrifuged and 
supernatants, containing highly soluble di-NAGs and the resulting glucosamine dimers, 
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were measured by MALDI upon evaporation of the buffer. MALDI analyses were kindly 
done by N. Schilling (Institute of Organic chemistry, University of Tübingen). 
 
 
4.3.6 In silico docking of TLR2-chitin interactions and modeling of TLR2 mutations 
 
The molecular structure of human TLR2 was extracted from PDB entry 2z7x (Jin et al. 
2007) using AutoDOCK software. Dockings were focused on the hydrophobic cavity of 
TLR2, where lipopeptide ligands and chitin bind. The TLR2-chitin 10 (10 NAGs) complex 
was generated based on results obtained from the docking of chitin 5 with additional 
manual adjustments, changing the orientation of the NAG chain while keeping the 
binding position. The TLR2-SSL3 structure was from PDB entry 5d3i (Koymans et al. 2015) 
and the docking and modeling studies were carried out by M. Frank from Biognos, 
Sweden. Figures showing the position and effects of mutated residues were generated in 
Pymol 1.4.1. (Schrödinger) by A. Weber (Department of Immunology, University of 
Tübingen). For further setting information see manuscript Fuchs et al.,2018 (Fuchs et al. 
2018). 
 
 
4.3.7 Mice and bone marrow derived macrophages (BMDMs)  
 
Upon sacrificing of the mice using CO2 and excision of femurs and tibia, bones were 
opened by cutting the edges from the bones with sterile surgical scissors, the bone 
marrow flushed out using insulin syringes and the isolated bone marrow maintained in 
RPMI medium supplemented with EDTA (2 mM). The bone marrow cells were washed 
once with complete RPMI, passed through a 70 µm strainer to obtain a single-cell 
suspension and were differentiated in complete RPMI for 6 days supplemented with  
10% vol/vol supernatant of L929 culture containing GM-CSF. Here, 3x10^7 cells were 
plated in 10 cm petri dishes with a 10 ml total volume for differentiation. The resulting 
BMDMs were harvested on day 6, seeded in 96 well plates (100,000 cells/well) in 
complete RPMI and stimulated the next day for 18 h using ligands and concentrations 
stated in the figures (ligand information see Table 6). Supernatants were analyzed for 
murine TNF or IL-6 levels by ELISA.   
 
Excised femurs and tibia from Tlr2, Tlr1 and Tlr6 KO mice, all from mice with a C57BL/6 
background, were a gift from T. Roger (Centre hospitalier universitaire Vaudois, Lausanne, 
Switzerland). Myd88 and Tlr2 KO mice, originally a gift from H. Wagner (Ludwigs-
Maximilian University, Munich), and C57BL/6 WT were maintained and sacrificed in the 
local animal facility (Department of Immunology, University of Tübingen) using CO2 and 
following local institutional guidelines and protocols. All mice were 14-16 weeks old. 
Experiments using Tlr2, Tlr1 and Tlr6 KO mice BMDMs were done together with  
Z. Bittner and F. Herster (Department of Immunology, University of Tübingen).   
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Table 5. List of antibodies for immunoblotting. 
Antibodies  
Host 
species 
Working 
dilution 
Manufacturer 
(Cat.#) 
Blocking  Blotting 
Primary  
Anti-Flag  Rabbit 1:1000 Sigma, (F7425) 5% BSA, 1h RT  5% BSA, 4°C O/N 
Anti-GFP Rabbit 1:2000 Sigma, (G1544) 5% BSA, 1h RT  5% BSA, 4°C O/N 
Anti-HA, C29F4  Rabbit 1:1000 
Cell Signaling 
(#3724) 
5% BSA, 1h RT  
5% BSA, 4°C O/N 
Anti-MyD88, 
4D6  
Mouse 1:1000 
Thermo Fisher 
(MA5-16231) 
5% Milk, 1h RT  5% BSA, 4°C O/N 
Anti-MyD88, 
D80F5  
Rabbit 1:1000 
Cell Signaling 
(#4283) 
5% BSA, 1h RT  5% BSA, 4°C O/N 
Secondary  
Anti-mouse, 
HRP conjugated 
Goat 1:4000 
Promega 
(W4028)   
5% BSA, 2h RT  
Anti-rabbit HRP 
conjugated 
Goat 1:4000 
Vector 
Laboratories 
(PI-1000)   
5% BSA, 2h RT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSA: Bovine serum albumin; RT: room temperature; O/N: over night 
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Table 6. List of Ligands and Inhibitors.  
Receptor Ligand/Inhibitor  Concentration Catalog ID Origin 
TLR2  
C-10-15 (chitosan) 0,5 to 10 µM OC28900 
Carbosynth, self-
acetylated 
Zymosan 100 µg/ml tlrl-zyn Invivogen 
Zymosan depleted 100 µg/ml tlrl-dzn Invivogen 
C-5 0,2 to 10 µM 55/14-0050 Isosep 
SSL3, staphylococcal 
superantigen-like 3 
10 nM 
 
Koymans et al., 
2015; SSL3 
(residues 134-326) 
TLR2-TLR1 Pam3CSK4 10 pM to 5 µM tlrl-pms Invivogen 
TLR2-TLR6 Pam2CSK4 1 pM to 5 µM tlrl-pm2s-1 Invivogen 
TLR9 CpG 2006 1 to 2.5 µg/ml 
 
TIB MOLBIOL, 
Berlin 
TLR5 Flagellin 50 ng/ml tlrl-stfla Invivogen 
NOD 2  
Muramyl dipeptide 
(MDP) 
200 nM tlrl-mdp Invivogen 
Dectin-1  Zymosan 100 µg/ml tlrl-zyn Invivogen 
BCR 
Anti-human IgM, 
Fc5µ 
5 μg/mL 
309-005-
095 
Jackson 
ImmunoResearch 
TLR4 Polymyxin B 10 µg/ml 21850029 Thermo Fisher 
 
 
 
Table 7. List of siRNA pools used for knock-down experiments 
Name of siRNA pool   Catalog ID 
siGENOME Human TLR1 (7096) siRNA-SMARTpool M-008086-01 
siGENOME Human TLR6 (10333) siRNA-SMARTpool M-005156-01 
siGENOME Human TLR5 (7100) siRNA-SMARTpool M-008089-01 
siGENOME Non-Targeting Pool#1 D-001206-13-05 
siGENOME H TLR2 (7097) siRNA -SMART pool  M-005120-03-005 
ON-TARGETplus MYD88 siRNA - SMARTpool L-004769-00-0005 
all pools from Dharmacon, GE Healthcare  
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Table 8. List of plasmids. 
Gene to be expressed  Tag  Backbone Resistance  Origin  Notes  
Internal 
ID  
Original MYD88 plasmids, also used for qPCR          
MYD88 Isoform 1 - WT  N.A. pDONR221 Kanamycin  
Harvard plasmids ID: 
HsCD00296025 
lacks first 13 AA, closed construct  pEX 502 
MYD88 Isoform 2 - WT  N.A. pDONR207 Gentamycin Generated by O. Wolz lacks first 13 AA, closed construct  pOW 011 
MYD88 Isoform 3 - WT  N.A. pDONR207 Gentamycin GOI§ by GENEWIZ closed construct  pEX 503 
MYD88 Isoform 4 - WT  N.A. pDONR207 Gentamycin GOI by GENEWIZ closed construct pEX 504 
MYD88 Isoform 5 - WT  N.A. pDONR207 Gentamycin GOI by GENEWIZ closed construct pEX 505 
MYD88 Isoform 1 - L265P N.A. pDONR207 Gentamycin This study pEX-502 after mutagenesis  pYCG 054 
MYD88 Isoform 2 - L265P  N.A. pDONR207  Gentamycin Generated by O. Wolz lacks first 13 AA, closed construct  pOW 012 
MYD88 Isoform 3 - L265P  N.A. pDONR207  Gentamycin This study pEX-503 after mutagenesis  pYCG 060 
MYD88 Isoform 4 - L265P  N.A. pDONR207  Gentamycin This study pEX-504 after mutagenesis  pYCG 056 
MYD88 Isoform 5 - L265P  N.A. pDONR207  Gentamycin This study  pEX-505 after mutagenesis  pYCG 059 
Expression MYD88 plasmids            
MYD88 Isoform 1 - WT  N-SHA*  pTO-N-SH Ampicillin This study   pYCG 030 
MYD88 Isoform 2 - WT  N-SHA  pTO-N-SH Ampicillin Generated by O. Wolz   pOW 030 
MYD88 Isoform 3 - WT  N-SHA  pTO-N-SH Ampicillin This study    pYCG 033 
MYD88 Isoform 4 - WT  N-SHA  pTO-N-SH Ampicillin This study   pYCG 036 
MYD88 Isoform 5 - WT  N-SHA  pTO-N-SH Ampicillin This study   pYCG 038 
MYD88 Isoform 1 - L265P  N-SHA  pTO-N-SH Ampicillin This study   pYCG 171 
MYD88 Isoform 2 - L265P  N-SHA  pTO-N-SH Ampicillin Generated by O.Wolz   pOW 031 
MYD88 Isoform 3 - L265P  N-SHA  pTO-N-SH Ampicillin This study    pYCG 174 
MYD88 Isoform 4 - L265P  N-SHA  pTO-N-SH Ampicillin This study   pYCG 177 
MYD88 Isoform 5 - L265P  N-SHA  pTO-N-SH Ampicillin This study   pYCG 180 
MyD88 (Isof. 2) DD-INT 
ProtA-
Myc 
pT-Rex-
DEST30 
Ampicillin Generated by J.George 
Stop codon at AA 157, used in 
(George et al. 2011) 
pJG-072 
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Gene to be expressed  Tag  Backbone Resistance  Origin  Notes  Internal ID  
PRRs, expression plasmids           
TLR2 - WT  N-Flag+ pcDNA3 Ampicillin Gift from I. Bekeredjian-Ding pEX 073 
TLR2 - L328W N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 068 
TLR2 - V348L N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 069 
TLR2 - V348W N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 070 
TLR2 - V348Y N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 071 
TLR2 - F349W N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 072 
TLR2 - F349Y N-Flag  pcDNA3 Ampicillin Generated by M.Dang pEX 073 after mutagenesis  pMD 073 
TLR6 - P680H HA  pcDNA 3.1 Ampicillin Gift from L.Quintana Dominant negative mutation  pEX 634 
TLR10 HA  pCMV Ampicillin Gift from U.Hasan   pEX 681 
TLR10 YFP pcDNA 3.1 Ampicillin Internal Stock   pEX 679 
TLR9 N-Flag  pcDNA 3.1 Ampicillin Gift from A. Dalpke   pEX 013 
NOD-2 N-Flag  pCMV  Kanamycin  Gift from T. Kufer    pEX 621 
Dectin-1 (BGR-A) None  pcDNA  Ampicillin Gift from G. Brown    pEX 619 
Others              
NF-κB reporter N.A. pNF-kB Ampicillin Stratagene 
Firefly luciferase reporter gene the under 
control of NF-κB p65 consensus promotor 
sequence 
Renilla Luciferase  N.A. pRL-TK Ampicillin  Promega Renilla luciferase, continuous expression  
eGFP  N.A. pC1-EGFP Ampicillin Gift from S.Dempe    pEX 008 
Empty  N.A. pTO-N-SH Ampicillin Gift from A. Pichlmaira Adds N-terminal SHA- tag pEX 144 
Empty  N.A. pcDNA3 Ampicillin Addgene Adds N-terminal Flag- tag pEX 021 
All gene sequences are human sequences otherwise stated. More details about Names and Institutions see Table S1.  
N.A.: No applicable; §GOI: Gene of interest; * N-SHA: fused StrepIII-Hemagglutinin tag at the N-terminus; +N-Flag: fused Flag tag at the N-
terminus. 
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Table 9. Sequences of mutagenesis primers.  
Primer name Sequence (5‘ to 3‘) Internal ID  Designed by  
Mutagenesis primers for all MYD88 splice variants plasmids  
L265P- Forward  gcccatcagaagcgaccgatccccatcaagtac AWm460 Hui Wang 
L265P- Reverse   gtacttgatggggatcggtcgcttctgatgggc AWm461 Hui Wang 
Mutagenesis (insertion*) primers for MYD88 splice variant 4 and 5 
Myd88_insert_Fwd ccatcagaagcgactgatccccatcaagtacaaggcaatgaagaaaggacccagctttc AWm537 In this study 
Myd88_insert_Rev gaaagctgggtcctttcttcattgccttgtacttgatggggatcagtcgcttctgatgg AWm538 In this study 
Mutagenesis primers for TLR2 constructs  
L328W-Forward aagtgaatataaagtgctccaatcataaaataagtaaaaccttggaatatgcagcct AWm543 A. Weber 
L328W-Reverse aggctgcatattccaaggttttacttattttatgattggagcactttatattcactt AWm544 A. Weber  
V348L-Forward aagtaaacaaggaaccagaaaaagtttactgttttctactgtgattc AWm545 A. Weber 
V348L-Reverse gaatcacagtagaaaacagtaaactttttctggttccttgtttactt AWm546 A. Weber  
V348W-Forward aatgttgtgaaagtaaacaaggaaccagaaaccatttactgttttctactgtgattcttttaactc AWm547 A. Weber  
V348W-Reverse gagttaaaagaatcacagtagaaaacagtaaatggtttctggttccttgtttactttcacaacatt AWm548 A. Weber  
V348Y-Forward gtaaacaaggaaccagaaaatatttactgttttctactgtgattcttttaactctttc AWm549 A. Weber  
V348Y-Reverse gaaagagttaaaagaatcacagtagaaaacagtaaatattttctggttccttgtttac AWm550 A. Weber  
F349W-Forward gtgaaagtaaacaaggaaccagccaaactttactgttttctactgtgattcttttaac AWm551 A. Weber  
F349W-Reverse gttaaaagaatcacagtagaaaacagtaaagtttggctggttccttgtttactttcac AWm552 A. Weber  
F349Y-Forward gtaaacaaggaaccagataaactttactgttttctactgtgattctttta AWm553 A. Weber  
F349Y-Reverse taaaagaatcacagtagaaaacagtaaagtttatctggttccttgtttac AWm554 A. Weber  
*Insertion of 30 bp to the end of CDS of variant 4 and 5 due to interruption of the natural stop codon when having L265P mutation.  
Hui Wang, alumna Department of Immunology, University of Tübingen.  
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Table 10. Sequences and information of primers used for qPCR. 
Detection  Forward primer (5' to 3') Info primer Reverse primer (5' to 3') Info primer Amplicon size Efficiency  
MYD88 agaggttggctagaaggcc Lenght: 19 gcacctggagagaggctg Lenght: 18 124 bp 105% 
Variant 1  ID: AWq_029 GC%: 57.89 ID: AWq_030 GC%: 66.67     
    Tm: 58.70°C   Tm: 59.64°C     
    Exon:4   Exon:4-5     
MYD88 cccagcattgaggaggattgc Lenght: 21 ctcaggcatatgccccaggg Lenght: 20 159 bp n.av. 
Variant 2 ID: AWq_031 GC%: 57.14 ID: AWq_037 GC%: 65     
    Tm: 61.36°C   Tm: 62.42°C     
    Exon:1-2   Exon: 2-3     
MYD88 tgggacccagcattgggc Lenght: 18 tccttgctctgcaggtaatc Lenght: 20 247 bp 66.39% 
Variant 3 ID: AWq_046 GC%: 66.67 ID: AWq_047 GC%: 50     
    Tm: 62.38   Tm: 57.3     
    Exon: 1-3   Exon:4     
MYD88 atgaccccctgggtgcc Lenght: 17 gcacctggagagaggctg Lenght: 18 104 bp 106% 
Variant 4 ID: AWq_035 GC%: 70.59 ID: AWq_030 GC%: 66.67     
    Tm: 61.04°C   Tm: 59.42°C     
    Exon:2-4   Exon:4-5     
MYD88 ggacccagcattggtgcc Lenght: 18 gcacctggagagaggctg Lenght: 18 109 pb 108% 
Variant 5  ID: AWq_036 GC%: 66.67 ID: AWq_030 GC%: 66.67     
    Tm: 61.07°C   Tm: 59.42°C     
    Exon:1-4   Exon:4-5     
GAPDH agccacatcgctcagacac Lenght: 19 gcccaatacgaccaaatcc  Lenght: 19 66 bp 75.4% 
  Awq_026 Exon:2 Awq_027 Exon:3     
n.av.= not available  
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A.1 Supplementary Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b a
s
Figure S1. Plasmid maps from (a) empty destination vector pTO-N-SH, modified from pCDNA5/FRT and  
(b) after cloning of the CDS of MyD88 isoform 3. Maps generated in Geneious Pro version 5.5.9.  
Figure S2. Assesing MyD88 isoform 3 and 5 potential inhibitory effect.  DLA measurements 
of NF-B activation in HEK 293T cells lysates upon transient transfection with four different amounts 
of MyD88 isoforms 3 and 5, together with NF-B-inducible firefly luciferase and constitutive Renilla 
luciferase reporter. Cells were stimulated for 18 h with flagellin upon 32 h transfection. Threshold for 
activation was set at 5 RLU. Graph is representative of n=3 showing means+SD of triplicates.  
EV: empty vector; RLU: relative luminescence units. 
 
 
Figure S3. Assesing MyD88 isoform 3 and 5 potential inhibitory effect.  DLA measurements 
of NF-B activation in HEK 293T cells lysates upon transient transfection with four different amounts 
of MyD88 isoforms 3 and 5, together with NF-B-inducible firefly luciferase and constitutive Renilla 
luciferase reporter. Cells were stimulated for 18 h with flagellin upon 32 h transfection. Threshold for 
activation was set at 5 RLU. Graph is representative of n=3 showing means+SD of triplicates.  
EV: empty vector; RLU: relative luminescence units. 
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Figure S5. Primer pair generated an amplicon of unexpected length for MyD88 isoform 1. 
(a) Melting curves of amplicons for MyD88 isoforms 1 to 5 (left to right) for BJAB cells or entry vectors 
for the different MyD88 isoforms. RT-qPCR was performed using SybrGreen and primers specific for 
isoforms 1-5 of MyD88 (Table 10). Melting curves from BJAB sample (violet curve) and entry vectors 
from all MyD88 isoforms (blue for variants 1,2,4 and red for variants 3,5) are compared. Arrow points 
at the different melting curves from isoform 1. (b) Sequence alignment of isoform 1 reference 
(NM_001172567.1) and sequence of amplicon of BJAB sample from (a). Picture generated in Geneious 
Pro version 5.5.9. 
 
Figure S6. Increased mRNA expression of MyD88 isoform 3 upon TLR stimulation. 
mRNA quantification of MyD88 isoforms (isof.) in human PBMCs stimulated as indicated, n=3. PBMCs 
were isolated from fresh blood and stimulated in a reverse time point schedule. Upon stimulation cells 
were lysed and RNA was isolated and transcribed to cDNA.  mRNA quantification was done by RT-qPCR 
using primers described in Table 10. Shown mean+SEM; *p<0.05 according to Two-way ANOVA; 
variables: isoform and stimuli. Figure S7. Primer pair generated an amplicon of unexpected 
length for MyD88 isoform 1. (a) Melting curves of amplicons for MyD88 isoforms 1 to 5 (left to 
right) for BJAB cells or entry vectors for the different MyD88 isoforms. RT-qPCR was performed using 
SybrGreen and primers specific for isoforms 1-5 of MyD88 (Table 10). Melting curves from BJAB 
sample (violet curve) and entry vectors from all MyD88 isoforms (blue for variants 1,2,4 and red for 
variants 3,5) are compared. Arrow points at the different melting curves from isoform 1. (b) Sequence 
alignment of isoform 1 reference (NM_001172567.1) and sequence of amplicon of BJAB sample from 
(a). Picture generated in Geneious Pro version 5.5.9. 
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Figure S8. Increased mRNA expression of MyD88 isoform 3 upon TLR stimulation. 
mRNA quantification of MyD88 isoforms (isof.) in human PBMCs stimulated as indicated, n=3. PBMCs 
were isolated from fresh blood and stimulated in a reverse time point schedule. Upon stimulation cells 
were lysed and RNA was isolated and transcribed to cDNA.  mRNA quantification was done by RT-qPCR 
using primers described in Table 10. Shown mean+SEM; *p<0.05 according to Two-way ANOVA; 
variables: isoform and stimuli.  
 
Figure S9. Example of Standard curves from RT-qPCR primers. Primers sequences described in Table  
10. Templates were generated constructs listed in Table 8. Tritation was done with consecutive 1:5 
dilutions. Values are triplicates.Figure S10. Increased mRNA expression of MyD88 isoform 3 
upon TLR stimulation. 
mRNA quantification of MyD88 isoforms (isof.) in human PBMCs stimulated as indicated, n=3. PBMCs 
were isolated from fresh blood and stimulated in a reverse time point schedule. Upon stimulation cells 
were lysed and RNA was isolated and transcribed to cDNA.  mRNA quantification was done by RT-qPCR 
using primers described in Table 10. Shown mean+SEM; *p<0.05 according to Two-way ANOVA; 
variables: isoform and stimuli.  
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Figure S14. Representative Sashimi plot out of 72 Ovarian cancer samples; RNA seq data obtain 
from ICGC libraries. Y axis (RPKM) represent exon reads and arcs represent exon junctions. The 
width of the arc is proportional to the number of junctions.  RPKM: reads per kilobase million. Plot 
done by  
S. Fillinger from QbiQ, University of Tübingen.  
 
Figure S15.  TLR2 knockdown in human macrophages showed reduced chitin-
response. IL-6 released from human primary monocyte-derived macrophages (MoMacs, 
n=5) treated with non-targeting (NT), TLR2- or MyD88-specific siRNA. Data represents 
(mean+SEM) combined from ‘n’ biological replicates.  
* p<0.05 according to Wilcoxon signed rank sum. Experiments done by M. Dang and K. 
Fuchs from University of Tübingen. Materials and Methods described in the 
manuscript.Figure S16. Representative Sashimi plot out of 72 Ovarian cancer samples; RNA seq 
data obtain from ICGC libraries. Y axis (RPKM) represent exon reads and arcs represent exon 
junctions. The width of the arc is proportional to the number of junctions.  RPKM: reads per kilobase 
million. Plot done by  
S. Fillinger from QbiQ, University of Tübingen.  
Reporter Target Slope Y-intercept r
2 Efficiency %
SYBR Isoform 3 -4.522 8.422 0.974 66.392
SYBR Isoform 4 -3.187 8.218 0.995 105.961
SYBR Isoform 5 -3.138 8.644 0.994 108.288
Figure S11. Example of Standard curves from RT-qPCR primers. Primers sequences described in 
Table  10. Templates were generated constructs listed in Table 8. Tritation was done with 
consecutive 1:5 dilutions. Values are triplicates.  
 
 
Figure S12. Example of Standard curves from RT-qPCR primers. Primers sequences described in 
Table  10. Templates were generated constructs listed in Table 8. Tritation was done with 
consecutive 1:5 dilutions. Values are triplicates.  
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Figure S17.  TLR2 knockdown in human macrophages showed reduced chitin-response. IL-6 released 
from human primary monocyte-derived macrophages (MoMacs, n=5) treated with non-targeting (NT), 
TLR2- or MyD88-specific siRNA. Data represents (mean+SEM) combined from ‘n’ biological replicates.  
* p<0.05 according to Wilcoxon signed rank sum. Experiments done by M. Dang and K. Fuchs from 
University of Tübingen. Materials and Methods described in the manuscript. 
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A.2 Supplementary Tables   
 
Table S1. List of references from table 1. 
TLR  References for ligands 
TLR2  
(Sato et al. 2003, O'Neill, Golenbock, and Bowie 2013, 
Leadbetter et al. 2002, Opal and Huber 2002, Erridge 
2010) 
TLR2 with TLR1  
(Ozinsky et al. 2000, Aliprantis et al. 1999, O'Neill, 
Golenbock, and Bowie 2013) 
TLR2 with TLR6 
(Takeuchi et al. 2001, Buwitt-Beckmann et al. 2005, 
Shibata et al. 2000, O'Neill, Golenbock, and Bowie 2013, 
Li et al. 2001) 
TLR3  
(O'Neill, Golenbock, and Bowie 2013, Liu and Ji 2014, 
Green et al. 2012) 
TLR4 with MD2  
(O'Neill, Golenbock, and Bowie 2013, Liu and Ji 2014, 
Opal and Huber 2002) 
TLR5  (O'Neill, Golenbock, and Bowie 2013) 
TLR7  (O'Neill, Golenbock, and Bowie 2013, Green et al. 2012) 
TLR8 (O'Neill, Golenbock, and Bowie 2013)  
TLR9  (O'Neill, Golenbock, and Bowie 2013, Liu and Ji 2014)  
TLR10 (human) (Regan et al. 2013) 
TLR11 (mouse) (O'Neill, Golenbock, and Bowie 2013, Liu and Ji 2014) 
TLR11 with TLR12 
(mouse) (Yarovinsky, Hieny, and Sher 2008, Raetz et al. 2013) 
TLR13 (mouse) 
(Wang, Chai, and Wang 2016, Hidmark, von Saint Paul, 
and Dalpke 2012) 
 
 
 
Table S2. List of Names and Institutions of persons providing certain plasmids. 
Names; Institutions  
Alexander Dalpke; Medical Microbiology, Heidelberg University, Germany 
Andreas Pichlmair; Max Planck Institute, Munich, Germany  
Gordon Brown; Aberdeen University, UK 
Goutham Pattabiraman; UCONN health Center, US 
Lluis Quintana-Murci; Institut Pasteur, Paris, France 
Isabel Bekeredjian-Ding; Medical Microbiology, Heidelberg University, Germany 
Julie George; (alumna) University of Tübingen, Germany  
Minh-Truong Dang; University of Tübingen, Germany   
Olaf-Oliver Wolz; (Doctoral thesis) University of Tübingen, Germany 
Sebastian Dempe; Krebsforschungszentrum, Heidelberg, Germany 
Thomas Kufer; Hohenheim University, Germany 
Uzma Hassan; University of London, United Kingdom 
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Table S3. Public IDs from RNAseq data  
ID # Origin 
 
ID # Origin 
 
ID # Origin 
 
ID # Origin 
 
ID # Origin 
 
ID # Origin 
4118819-bcell Bcell 
 
4107137 DLBCL 
 
4141476 DLBCL 
 
4100049 FL 
 
4131738 FL 
 
4177406 FL 
4122131-bcell Bcell 
 
4107559 DLBCL 
 
4145528 DLBCL 
 
4101626 FL 
 
4134005 FL 
 
4177601 FL 
4149880-bcell Bcell 
 
4107990 DLBCL 
 
4146301 DLBCL 
 
4101815 FL 
 
4136095 FL 
 
4177810 FL 
4160735-bcell Bcell 
 
4108101 DLBCL 
 
4147968 DLBCL 
 
4103141 FL 
 
4138059 FL 
 
4177844 FL 
4174884-bcell Bcell 
 
4109808 DLBCL 
 
4157186 DLBCL 
 
4103627 FL 
 
4138652 FL 
 
4177987 FL 
4118819-gcbcell GCBcell 
 
4111326 DLBCL 
 
4158933 DLBCL 
 
4105105 FL 
 
4138885 FL 
 
4178655 FL 
4122131-gcbcell GCBcell 
 
4113140 DLBCL 
 
4159421 DLBCL 
 
4105782 FL 
 
4139212 FL 
 
4181037 FL 
4149880-gcbcell GCBcell 
 
4113971 DLBCL 
 
4161781 DLBCL 
 
4108588 FL 
 
4139483 FL 
 
4184011 FL 
4160735-gcbcell GCBcell 
 
4114033 DLBCL 
 
4163639 DLBCL 
 
4108988 FL 
 
4144366 FL 
 
4187640 FL 
4174884-gcbcell GCBcell 
 
4115001 DLBCL 
 
4166940 DLBCL 
 
4108992 FL 
 
4145056 FL 
 
4188800 FL 
4110996 BL_solid 
 
4116268 DLBCL 
 
4167381 DLBCL 
 
4109142 FL 
 
4145391 FL 
 
4188900 FL 
4112512 BL_solid 
 
4117030 DLBCL 
 
4167925 DLBCL 
 
4109956 FL 
 
4147081 FL 
 
4189200 FL 
4119027 BL_solid 
 
4119279 DLBCL 
 
4168738 DLBCL 
 
4110378 FL 
 
4147360 FL 
 
4190929 FL 
4125240 BL_solid 
 
4120157 DLBCL 
 
4169012 DLBCL 
 
4112447 FL 
 
4148261 FL 
 
4198542 FL 
4127766 BL_solid 
 
4120193 DLBCL 
 
4170577 DLBCL 
 
4112817 FL 
 
4148771 FL 
 
4199848 FL 
4130003 BL_solid 
 
4121621 DLBCL 
 
4171586 DLBCL 
 
4113191 FL 
 
4149246 FL 
 
4199996 FL 
4133511 BL_solid 
 
4122063 DLBCL 
 
4171810 DLBCL 
 
4113825 FL 
 
4150549 FL 
 
4100636 FL-DLBCL 
4144633 BL_solid 
 
4124188 DLBCL 
 
4171946 DLBCL 
 
4118156 FL 
 
4151028 FL 
 
4110120 FL-DLBCL 
4146289 BL_solid 
 
4124791 DLBCL 
 
4173863 DLBCL 
 
4119463 FL 
 
4158268 FL 
 
4111337 FL-DLBCL 
4162611 BL_solid 
 
4128849 DLBCL 
 
4176046 DLBCL 
 
4119702 FL 
 
4158483 FL 
 
4131213 FL-DLBCL 
4163741 BL_solid 
 
4128852 DLBCL 
 
4176133 DLBCL 
 
4120879 FL 
 
4158726 FL 
 
4131744 FL-DLBCL 
4177434 BL_solid 
 
4130051 DLBCL 
 
4176325 DLBCL 
 
4121263 FL 
 
4159170 FL 
 
4132950 FL-DLBCL 
4177856 BL_solid 
 
4130194 DLBCL 
 
4177842 DLBCL 
 
4121361 FL 
 
4160069 FL 
 
4136702 FL-DLBCL 
4178518 BL_solid 
 
4130865 DLBCL 
 
4179894 DLBCL 
 
4121974 FL 
 
4160468 FL 
 
4144131 FL-DLBCL 
4182393 BL_solid 
 
4131257 DLBCL 
 
4181460 DLBCL 
 
4123945 FL 
 
4162154 FL 
 
4144951 FL-DLBCL 
4186812 BL_solid 
 
4133263 DLBCL 
 
4183136 DLBCL 
 
4124432 FL 
 
4163297 FL 
 
4145177 FL-DLBCL 
4189998 BL_solid 
 
4134434 DLBCL 
 
4184094 DLBCL 
 
4124542 FL 
 
4164330 FL 
 
4177376 FL-DLBCL 
4190495 BL_solid 
 
4135099 DLBCL 
 
4188879 DLBCL 
 
4124795 FL 
 
4165379 FL 
 
4183924 FL-DLBCL 
4193278 BL_solid 
 
4135278 DLBCL 
 
4189035 DLBCL 
 
4126692 FL 
 
4166503 FL 
 
4184437 FL-DLBCL 
4194218 BL_solid 
 
4137230 DLBCL 
 
4193638 DLBCL 
 
4128355 FL 
 
4170686 FL 
 
4186613 FL-DLBCL 
4194891 BL_solid 
 
4138464 DLBCL 
 
4193646 DLBCL 
 
4128435 FL 
 
4171706 FL 
   
4101316 DLBCL 
 
4138527 DLBCL 
 
4197155 DLBCL 
 
4128477 FL 
 
4171908 FL 
   
4102009 DLBCL 
 
4139696 DLBCL 
 
4198519 DLBCL 
 
4128970 FL 
 
4174905 FL 
   
4104105 DLBCL 
 
4140531 DLBCL 
 
4199714 DLBCL 
 
4131095 FL 
 
4175837 FL 
   
4105746 DLBCL 
 
4140544 DLBCL 
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